<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacokinet</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacokinet</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Clinical Pharmacokinetics</journal-title></journal-title-group><issn pub-type="ppub">0312-5963</issn><issn pub-type="epub">1179-1926</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11762427</article-id><article-id pub-id-type="pmcid-ver">PMC11762427.1</article-id><article-id pub-id-type="pmcaid">11762427</article-id><article-id pub-id-type="pmcaiid">11762427</article-id><article-id pub-id-type="pmid">39821208</article-id><article-id pub-id-type="doi">10.1007/s40262-024-01459-z</article-id><article-id pub-id-type="publisher-id">1459</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3223-670X</contrib-id><name name-style="western"><surname>Albanell-Fern&#225;ndez</surname><given-names initials="M">Marta</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2469-986X</contrib-id><name name-style="western"><surname>Rodr&#237;guez-Reyes</surname><given-names initials="M">Montse</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0845-8107</contrib-id><name name-style="western"><surname>Bastida</surname><given-names initials="C">Carla</given-names></name><address><email>cbastida@clinic.cat</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8128-345X</contrib-id><name name-style="western"><surname>Soy</surname><given-names initials="D">Dolors</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021018s57</institution-id><institution-id institution-id-type="GRID">grid.5841.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0247</institution-id><institution>Division of Medicines, Department of Pharmacy, Pharmacy Service, </institution><institution>Hospital Clinic of Barcelona, Universitat de Barcelona, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/054vayn55</institution-id><institution-id institution-id-type="GRID">grid.10403.36</institution-id><institution-id institution-id-type="ISNI">0000000091771775</institution-id><institution>August Pi i Sunyer Biomedical Research Institute (IDIBAPS), </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021018s57</institution-id><institution-id institution-id-type="GRID">grid.5841.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0247</institution-id><institution>Department of Pharmacology, Toxicology and Therapeutic Chemistry, School of Pharmacy and Food Science, </institution><institution>Universitat de Barcelona, </institution></institution-wrap>Barcelona, Spain </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>64</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">480462</issue-id><fpage>1</fpage><lpage>25</lpage><history><date date-type="accepted"><day>7</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>27</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-29 07:25:26.607"><day>29</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40262_2024_Article_1459.pdf"/><abstract id="Abs1"><p id="Par1">Population pharmacokinetic (popPK) models are an essential tool when implementing therapeutic drug monitoring (TDM) and to overcome dosing challenges in neonates in clinical practice. Since vancomycin, gentamicin, and amikacin are among the most prescribed antibiotics for the neonatal population, we aimed to characterize the popPK models of these antibiotics and the covariates that may influence the pharmacokinetic parameters in neonates and infants with no previous pathologies. We searched the PubMed, Embase, Web of Science, and Scopus databases and the bibliographies of relevant articles from inception to the beginning of February 2024. The search identified 2064 articles, of which 68 met the inclusion criteria (34 for vancomycin, 21 for gentamicin, 13 for amikacin). A one-compartment popPK model was more frequently used to describe the pharmacokinetics of the three antibiotics (91.2% vancomycin, 76.9% gentamicin, 57.1% amikacin). Pharmacokinetic parameter (mean &#177; standard deviation) values calculated for a &#8220;typical&#8221; neonate weighing 3 kg were as follows: clearance (CL) 0.34 &#177; 0.80 L/h for vancomycin, 0.27 &#177; 0.49 L/h for gentamicin, and 0.19 &#177; 0.07 L/h for amikacin; volume of distribution (<italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>): 1.75 &#177; 0.65 L for vancomycin, 1.54 &#177; 0.53 L for gentamicin, and 1.67 &#177; 0.27 L for amikacin for one-compartment models. Total body weight, postmenstrual age, and serum creatinine were common predictors (covariates) for describing the variability in CL, whereas only total body weight predominated for <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>. A single universal popPK model for each of the antibiotics reviewed cannot be implemented in the neonatal population because of the significant variability between them. Body weight, renal function, and postmenstrual age are important predictors of CL in the three antibiotics, and total body weight for <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>. TDM represents an essential tool in this population, not only to avoid toxicity but to attain the desired pharmacokinetic/pharmacodynamic index. The characteristics of the neonatal population, coupled with the lack of prospective studies and external validation of most models, indicate a need to continue investigating the pharmacokinetics of these antibiotics in neonates.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40262-024-01459-z.</p></sec></abstract><funding-group><award-group><funding-source><institution>Universitat de Barcelona</institution></funding-source></award-group><open-access><p>Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d33e198"><title>Key Points</title><p id="Par3">
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">The significant variability in pharmacokinetics between neonatal populations with vancomycin, gentamicin, and amikacin makes a universal population pharmacokinetic model for each antibiotic unfeasible.</td></tr><tr><td align="left" colspan="1" rowspan="1">Total body weight, postmenstrual age, and serum creatinine were the covariates most frequently included to explain variability in drug clearance. The primary explanatory factor for variability in the volume of distribution was total body weight.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec2"><title>Introduction</title><p id="Par4">Infections remain a leading cause of death in neonates [<xref ref-type="bibr" rid="CR1">1</xref>]. Systemic infections cause about 2.3 million neonatal deaths each year globally [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The ethical, logistical, regulatory, and technical difficulties associated with conducting studies on newborns have prevented them from being considered a high-priority population for inclusion in clinical trials, despite their high prevalence of infections [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Of 40 antibiotics approved for use in adults since 2000, only four have included dosing information for neonates in their labeling [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par5">Misuse of antibiotics or inadequate dosing can lead to treatment failure and the emergence of drug-resistant pathogens, resulting in longer hospital stays and increased mortality [<xref ref-type="bibr" rid="CR5">5</xref>]. Neonates exhibit major and rapid physiological changes in the distribution, metabolism, and excretion of drugs administered intravenously [<xref ref-type="bibr" rid="CR6">6</xref>]. The neonatal population is characterized by a higher body water percentage, reduced protein binding, and decreased renal clearance at birth, which gradually increases as the renal system matures [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Fat and extracellular water proportions vary extensively across ages. Fat percentage increases with age (6% in premature infants, 13.4% in full-term infants, 18% in adults, and 30% in elderly people), whereas the water proportion decreases (80% in premature infants, 70% in full-term infants, 60% in adults, and 54% in elderly people) [<xref ref-type="bibr" rid="CR9">9</xref>]. Compared with adults, newborns have higher inter- and intraindividual variability in pharmacokinetics, especially for antibiotics [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par6">The pharmacokinetic differences between newborns and adults justify specific pharmacokinetic studies in neonates. After the introduction of the nonlinear mixed-effects modeling methodology, the population pharmacokinetic (popPK) approach became a reference technique in the neonate population. The population-based modeling method assesses both intra- and inter-individual variability. This allows for the determination of optimal dosing regimens by identifying and quantifying sources of pharmacokinetic variability, thereby improving our understanding and optimization of pharmaceutical interventions [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. This method has an advantage over classical pharmacokinetic analysis in that the effects of covariates such as age, weight, disease state, and organ function on pharmacokinetic parameters can be obtained through sparse sampling from each subject. This reduces the need for blood sampling, which facilitates this type of study because it is unpractical and unethical to take multiple blood extractions from neonates [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par7">Choosing the appropriate popPK model for each antibiotic is essential in clinical practice, as it improves therapeutic drug monitoring (TDM) by providing better individualized predictions [<xref ref-type="bibr" rid="CR5">5</xref>]. Model-informed precision dosing (MIPD) is a clinical strategy that employs mathematical and pharmacokinetic/pharmacodynamic models, along with patient-specific data, to optimize and personalize drug-dosing regimens. This approach leverages prior knowledge (such as population-based models) and real-time patient information (such as drug concentrations and clinical responses) to achieve the best therapeutic outcomes while minimizing adverse effects [<xref ref-type="bibr" rid="CR13">13</xref>]. However, the performance of most of the published popPK models remains unknown in other groups of patients than those used for its development [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Other previous reviews of popPK models have been conducted in pediatrics, including neonates, infants, and children [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. However, we focused only on the neonatal and infant population because of its specific characteristics and the remaining knowledge gaps in this population, which may account for the high intra-individual variability and may predict dosing. In addition, it includes common antibiotics used in clinical practice and candidates for TDM, allowing us to compare the covariates influencing each of them.</p><p id="Par8">The aim of the present study was to review the popPK models of the most widely prescribed antibiotics that are subject to TDM (vancomycin, gentamicin, and amikacin) in neonates and infants and to determine the applied structural models in this population. We analyzed the covariates that significantly influence the pharmacokinetics of each antibiotic and compared the standardized pharmacokinetic parameters (clearance [CL] and volume of distribution [V<sub>d</sub>]) of the studies included. We also collected the pharmacodynamic targets of each study included.</p></sec><sec id="Sec3"><title>Search Methodology</title><sec id="Sec4"><title>Literature Search Strategy</title><p id="Par9">We searched the MEDLINE (via PubMed), Embase, Web of Science, and Scopus databases from inception to the beginning of February 2024 using the following combination of terms for each antibiotic: (vancomycin OR gentamicin OR amikacin) AND (pharmacokinetic model OR pharmacokinetic analysis OR population pharmacokinetics) AND (newborn OR neonate). The initial search was limited to studies performed in humans that described popPK models of the antibiotics chosen. We also inspected the bibliographies of relevant articles.</p></sec><sec id="Sec5"><title>Inclusion and Exclusion Criteria</title><p id="Par10">All articles had to meet the following criteria: (i) observational studies or clinical trials describing popPK models in neonates and infants with no previous pathologies, including those with patent ductus arteriosus, (ii) intravenous administration of the antibiotic, (iii) gestational age (GA) &#8804; 44 weeks, and (iv) written in English, Spanish, French, or German.</p><p id="Par11">We excluded the following: (i) articles lacking equations to explain the effect of covariates on pharmacokinetic parameters and mean values of the pharmacokinetic parameters, (ii) reviews of published popPK models, (iii) validation studies for published popPK models, (iv) popPK models in neonates undergoing extracorporeal membrane oxygenation or controlled hypothermia and pathological conditions such as cystic fibrosis or hypoxic&#8211;ischemic encephalopathy, (v) studies including neonates and other populations (young infants, children, or adults) for model development, and (vi) studies for which the full text was not available upon request to the author.</p></sec><sec id="Sec6"><title>Data Extraction</title><p id="Par12">One investigator reviewed the literature by assessing the titles and abstracts according to the inclusion criteria. Any discrepancies were settled by consensus with a second investigator. One investigator extracted the following data from the studies: years of study duration, study design, country, statistical modeling software, total number of samples and patients, population characteristics, structural pharmacokinetic model, developed model for calculating the following pharmacokinetic parameters: clearance (CL), intercompartmental clearance (<italic toggle="yes">Q</italic>), volume of distribution (<italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>), volume of distribution of central compartment (V<sub>c</sub>), volume of distribution of peripheral compartment (<italic toggle="yes">V</italic><sub><italic toggle="yes">p</italic></sub>), and their variability, the included covariates in each equation, as well as the mean CL in L/h/kg and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> in L/kg, as well as the pharmacodynamic target. CL and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> standardized by the mean or median weight of the included population were calculated manually if such data were not provided in the article but could be calculated from the information provided in the text. In that case, the weight used is specified under the CL or <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> value.</p><p id="Par13">To describe the characteristics of the population included in each study, the range for GA in weeks, postnatal age (PNA) in days, postmenstrual age (PMA) or post-conceptional age (PCA) in weeks, and total body weight (WT) expressed as mean &#177; SD or median (range) were recorded. Some studies included the PCA instead of the PMA, and we included this information, even though the American Academy of Pediatrics Committee on the Fetus and Newborn [<xref ref-type="bibr" rid="CR18">18</xref>] recommend that PCA should no longer be used in clinical pediatrics.</p></sec></sec><sec id="Sec7"><title>Characteristics of Population Pharmacokinetic Models</title><p id="Par14">A total of 2064 articles were identified. After removing duplicates, 887 relevant studies were screened according to the title and abstract. Finally, 178 full texts were assessed for eligibility, and 68 of these were included in this review (34 for vancomycin, 21 for gentamicin, and 13 for amikacin) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The year of publication ranged from 1982 until the end of 2023.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flow chart of the article selection process. Abbreviations: ECMO: extracorporeal membrane oxygenation; I.M: intramuscular</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40262_2024_1459_Fig1_HTML.jpg"/></fig></p><sec id="Sec8"><title>Vancomycin</title><p id="Par15">Vancomycin had the highest number of popPK models in the literature, totaling 36 across 34 studies. Although the study years ranged from 1983 to 2021, most models were developed after the year 2000. All studies except Cristea et al. [<xref ref-type="bibr" rid="CR19">19</xref>] were conducted in only one country and mostly in a single hospital. The studies included neonates ranging in age from 0 to 562.8 days, GA from 22 to 42.1 weeks, and PMA from 22 to 110 weeks. The WT at the time of the study ranged from 0.32 to 14.9 kg. Nonlinear mixed&#8208;effects modeling was the most widely used approach for describing vancomycin popPK models in neonates, with most (25 of 36 models [69.4%]) using NONMEM<sup>&#174;</sup> statistical modeling software to estimate the individual pharmacokinetic parameters. Other studies used a Bayesian forecasting approach (Abbott Base Pharmacokinetic System, ADAPT II, Pumas or Phoenix<sup>TM</sup> NLME) to calculate pharmacokinetic parameters. Jarugula et al. [<xref ref-type="bibr" rid="CR20">20</xref>] used the largest number of vancomycin samples (<italic toggle="yes">n</italic> = 2471) to develop the model and the largest sample of patients (<italic toggle="yes">n</italic> = 934). Vancomycin popPK were best described by a one-compartment (1-CMT) approach in 31 models and by a two-compartment (2-CMT) approach in five models. Seay et al. [<xref ref-type="bibr" rid="CR21">21</xref>] developed both a 1-CMT and a 2-CMT model using the same population. In most cases, studies with rich sampling found that a 2-CMT model [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref>] better described the pharmacokinetic parameters than did a 1-CMT model.</p></sec><sec id="Sec9"><title>Gentamicin</title><p id="Par16">A total of 26 models for gentamicin were described in 21 articles. The years of study ranged from before 1988 to 2013. Most models were developed in the Netherlands (<italic toggle="yes">n</italic> = 4) and the USA (<italic toggle="yes">n</italic> = 3). The studies included neonates ranging from 0 to 120 days, GA from 22 to 43 weeks, and PMA from 23.3 to 43.8 weeks. The WT at the time of the study ranged from 0.44 to 5.51 kg. The most-often used statistical modeling software was NONMEM<sup>&#174;</sup>, which was used in 14 of the 26 models described (53.8%). Fuchs et al. [<xref ref-type="bibr" rid="CR24">24</xref>] had the largest gentamicin (<italic toggle="yes">n</italic> = 3039) and patient (<italic toggle="yes">n</italic> = 1449) samples. Four authors [<xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR28">28</xref>] reported more than one model using different covariates in each one. Most commonly, a 1-CMT model was applied (<italic toggle="yes">n</italic> = 21) to describe gentamicin popPK in newborns. Three studies applied a 2-CMT model, and two studies used a 3-CMT model. Like the vancomycin studies, those with more samples better fit a 2-CMT or 3-CMT than a 1-CMT model to describe the pharmacokinetics of gentamicin.</p></sec><sec id="Sec10"><title>Amikacin</title><p id="Par17">The fewest popPK models were found for amikacin (<italic toggle="yes">n</italic> = 14 in 13 studies). The years of study ranged from 1987 to 2021. Most models were developed in Belgium (<italic toggle="yes">n</italic> = 5). The studies included neonates ranging from 0 to 86 days, GA from 24 to 43 weeks, and PMA from 24 to 51.4 weeks. The WT at the time of the study ranged from 0.39 to 5.04 kg. NONMEM<sup>&#174;</sup> was again the most used statistical modeling software, in 11 of the 14 models developed (78.6%). The largest amikacin samples (<italic toggle="yes">n</italic> = 2186) and neonatal population (<italic toggle="yes">n</italic> = 874) came from the study by De Cock et al. [<xref ref-type="bibr" rid="CR29">29</xref>]. Illamola et al. [<xref ref-type="bibr" rid="CR30">30</xref>] reported two popPK models using a different set of covariates. An external validation of published amikacin models in Indian term neonates found that the model from Illamola et al. provided the lowest relative median absolute prediction error and relative root mean square error [<xref ref-type="bibr" rid="CR31">31</xref>]. Smits et al. [<xref ref-type="bibr" rid="CR32">32</xref>] prospectively evaluated the model by De Cock et al. [<xref ref-type="bibr" rid="CR29">29</xref>] and re-estimated it to develop a new one to optimize dosing in neonates with suboptimal trough levels. Eight studies used a 1-CMT approach to describe the data, and the remaining six studies used a 2-CMT approach. The largest population studies preferred 2-CMT over 1-CMT models to describe pharmacokinetic parameters.</p><p id="Par18">General information about the articles and the characteristics of the populations included is presented in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of the neonate population pharmacokinetic studies included in the review</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study, publication year</th><th align="left" colspan="1" rowspan="1">Years of study</th><th align="left" colspan="1" rowspan="1">Study design</th><th align="left" colspan="1" rowspan="1">Country</th><th align="left" colspan="1" rowspan="1">Statistical modeling software</th><th align="left" colspan="1" rowspan="1">Samples (N)</th><th align="left" colspan="1" rowspan="1">Patients (N)</th><th align="left" colspan="1" rowspan="1">Range GA (wk)</th><th align="left" colspan="1" rowspan="1">Range PNA (days)</th><th align="left" colspan="1" rowspan="1">Range PMA/PCA (wk)</th><th align="left" colspan="1" rowspan="1">Current weight (kg)</th><th align="left" colspan="1" rowspan="1">Structural pharmacokinetic model</th></tr></thead><tbody><tr><td align="left" colspan="12" rowspan="1"><bold>Vancomycin pharmacokinetic models</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Schaible et al., 1986 [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left" colspan="1" rowspan="1">1983</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">27&#8211;40</td><td align="left" colspan="1" rowspan="1">7&#8211;70</td><td align="left" colspan="1" rowspan="1">PCA 29&#8211;48</td><td align="left" colspan="1" rowspan="1">2.00 &#177; 1.22</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Asbury et al., 1993 [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left" colspan="1" rowspan="1">1990&#8211;1991</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">19<sup>a</sup></td><td align="left" colspan="1" rowspan="1">23&#8211;41</td><td align="left" colspan="1" rowspan="1">6&#8211;102</td><td align="left" colspan="1" rowspan="1">PCA 26.3&#8211;45.6</td><td align="left" colspan="1" rowspan="1">1.78 &#177; 1.08</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Seay et al., 1994 [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left" colspan="1" rowspan="1">1987&#8211;1989</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">520</td><td align="left" colspan="1" rowspan="1">192</td><td align="left" colspan="1" rowspan="1">22&#8211;42</td><td align="left" colspan="1" rowspan="1">1&#8211;73</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1.48 &#177; 1.05 (0.39&#8211;4.35)</td><td align="left" colspan="1" rowspan="1">1- or 2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Rodvold et al., 1995 [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left" colspan="1" rowspan="1">1989&#8211;1992</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Abbott Base Pharmacokinetic System</td><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">23&#8211;41</td><td align="left" colspan="1" rowspan="1">4&#8211;88</td><td align="left" colspan="1" rowspan="1">PCA 23.5&#8211;47.5</td><td align="left" colspan="1" rowspan="1">1.86<sup>b</sup> (0.58&#8211;4.82)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Burstein et al., 1997 [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">ADAPT II</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">29.4&#8211;34</td><td align="left" colspan="1" rowspan="1">4&#8211;117</td><td align="left" colspan="1" rowspan="1">PCA 30.8&#8211;48.7</td><td align="left" colspan="1" rowspan="1">1.19 &#177; 1.25</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Silva et al., 1998 [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left" colspan="1" rowspan="1">1993&#8211;1996</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Portugal</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">44</td><td align="left" colspan="1" rowspan="1">25&#8211;40</td><td align="left" colspan="1" rowspan="1">1&#8211;52</td><td align="left" colspan="1" rowspan="1">PCA 28&#8211;45</td><td align="left" colspan="1" rowspan="1">1.94 &#177; 0.95</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Grimsley and Thomson, 1999 [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">347</td><td align="left" colspan="1" rowspan="1">59</td><td align="left" colspan="1" rowspan="1">25&#8211;41</td><td align="left" colspan="1" rowspan="1">2&#8211;76</td><td align="left" colspan="1" rowspan="1">PCA 26&#8211;45</td><td align="left" colspan="1" rowspan="1">1.52 (0.57&#8211;4.23)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">De Hoog et al., 2000 [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left" colspan="1" rowspan="1">1992&#8211;1997</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Netherlands</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">108</td><td align="left" colspan="1" rowspan="1">24&#8211;41</td><td align="left" colspan="1" rowspan="1">3&#8211;27</td><td align="left" colspan="1" rowspan="1">PCA 26&#8211;42</td><td align="left" colspan="1" rowspan="1">1.0 (0.49&#8211;4.63)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Capparelli et al., 2001 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left" colspan="1" rowspan="1">1994&#8211;1997</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">1103</td><td align="left" colspan="1" rowspan="1">374</td><td align="left" colspan="1" rowspan="1">33.5 &#177; 6.0</td><td align="left" colspan="1" rowspan="1">70 &#177; 100</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">2.82 &#177; 2.33</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Kimura et al., 2004 [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">88</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">24.1&#8211;41.3</td><td align="left" colspan="1" rowspan="1">3&#8211;71</td><td align="left" colspan="1" rowspan="1">PCA 25.1&#8211;48.4</td><td align="left" colspan="1" rowspan="1">0.710&#8211;5.2</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Allegaert et al., 2007 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left" colspan="1" rowspan="1">2002&#8211;2006</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Belgium</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">648</td><td align="left" colspan="1" rowspan="1">249</td><td align="left" colspan="1" rowspan="1">23&#8211;34</td><td align="left" colspan="1" rowspan="1">1&#8211;27</td><td align="left" colspan="1" rowspan="1">PMA 24&#8211;37</td><td align="left" colspan="1" rowspan="1">1.25 &#177; 0.47</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Anderson et al., 2007 [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left" colspan="1" rowspan="1">2002&#8211;2005</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Belgium</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">604</td><td align="left" colspan="1" rowspan="1">214</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1&#8211;27</td><td align="left" colspan="1" rowspan="1">PMA 24&#8211;34</td><td align="left" colspan="1" rowspan="1">1.30 (0.42&#8211;2.6)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Marqu&#233;s-Mi&#241;ana et al., 2010 [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Spain</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">70</td><td align="left" colspan="1" rowspan="1">24&#8211;42</td><td align="left" colspan="1" rowspan="1">4&#8211;63</td><td align="left" colspan="1" rowspan="1">PMA 25.1&#8211;48.1</td><td align="left" colspan="1" rowspan="1">1.7 (0.7&#8211;3.7)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Lo et al., 2010 [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left" colspan="1" rowspan="1">1999&#8211;2005</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Malaysia</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">835</td><td align="left" colspan="1" rowspan="1">116</td><td align="left" colspan="1" rowspan="1">23&#8211;31</td><td align="left" colspan="1" rowspan="1">1&#8211;32</td><td align="left" colspan="1" rowspan="1">PMA 23&#8211;34</td><td align="left" colspan="1" rowspan="1">0.82 &#177; 0.11<sup>c</sup></td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Mehrotra et al., 2014 [<xref ref-type="bibr" rid="CR85">85</xref>]</td><td align="left" colspan="1" rowspan="1">1990&#8211;2007</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">267</td><td align="left" colspan="1" rowspan="1">134</td><td align="left" colspan="1" rowspan="1">23&#8211;41</td><td align="left" colspan="1" rowspan="1">1&#8211;121</td><td align="left" colspan="1" rowspan="1">PMA 24.6&#8211;44</td><td align="left" colspan="1" rowspan="1">2.5 &#177; 1.1</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Zhao et al., 2013 [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left" colspan="1" rowspan="1">2010&#8211;2011</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">France</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">207</td><td align="left" colspan="1" rowspan="1">116</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1&#8211;120</td><td align="left" colspan="1" rowspan="1">PMA 24.4&#8211;49.4</td><td align="left" colspan="1" rowspan="1">1.70 &#177; 0.96; 1.4 (0.46&#8211;5.68)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Frymoyer et al., 2014 [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left" colspan="1" rowspan="1">2007&#8211;2012</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">1702</td><td align="left" colspan="1" rowspan="1">249</td><td align="left" colspan="1" rowspan="1">22&#8211;42</td><td align="left" colspan="1" rowspan="1">0&#8211;173</td><td align="left" colspan="1" rowspan="1">PMA 24&#8211;54</td><td align="left" colspan="1" rowspan="1">2.9 (0.5&#8211;6.3)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Bhongsatiern et al., 2015 [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left" colspan="1" rowspan="1">2006&#8211;2011</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">528</td><td align="left" colspan="1" rowspan="1">152</td><td align="left" colspan="1" rowspan="1">24&#8211;33</td><td align="left" colspan="1" rowspan="1">15&#8211;41</td><td align="left" colspan="1" rowspan="1">PMA 28.5&#8211;39.4</td><td align="left" colspan="1" rowspan="1">1.5 (0.45&#8211;4.3)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Kato et al., 2017 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left" colspan="1" rowspan="1">2010&#8211;2015</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">Phoenix<sup>TM</sup> NLME</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">23.4&#8211;31.6</td><td align="left" colspan="1" rowspan="1">11&#8211;28</td><td align="left" colspan="1" rowspan="1">PCA 26.1&#8211;34.4</td><td align="left" colspan="1" rowspan="1">0.97 &#177; 0.23; 0.93 (0.69&#8211;1.43)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Song et al., 2017 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left" colspan="1" rowspan="1">2011&#8211;2016</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">Phoenix<sup>TM</sup> NLME</td><td align="left" colspan="1" rowspan="1">421</td><td align="left" colspan="1" rowspan="1">316</td><td align="left" colspan="1" rowspan="1">28&#8211;41</td><td align="left" colspan="1" rowspan="1">2&#8211;77</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">3.95 (1.25&#8211;7.62)</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Tseng et al., 2018 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left" colspan="1" rowspan="1">2011&#8211;2016</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Singapore</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">429</td><td align="left" colspan="1" rowspan="1">76</td><td align="left" colspan="1" rowspan="1">23.9&#8211;40.3</td><td align="left" colspan="1" rowspan="1">4&#8211;223.7</td><td align="left" colspan="1" rowspan="1">PMA 25.1&#8211;57.5</td><td align="left" colspan="1" rowspan="1">1.04 (0.32&#8211;6.59)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Li et al., 2018 [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">165</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">25.7&#8211;41.1</td><td align="left" colspan="1" rowspan="1">4&#8211;126</td><td align="left" colspan="1" rowspan="1">PMA 29&#8211;47.1</td><td align="left" colspan="1" rowspan="1">2.87 &#177; 0.89; 2.74 (1.4&#8211;5.6)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Chen et al., 2018 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left" colspan="1" rowspan="1">2014&#8211;2017</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">330</td><td align="left" colspan="1" rowspan="1">213</td><td align="left" colspan="1" rowspan="1">25&#8211;42</td><td align="left" colspan="1" rowspan="1">6&#8211;59</td><td align="left" colspan="1" rowspan="1">PMA 28&#8211;47.9</td><td align="left" colspan="1" rowspan="1">2.73 (0.88&#8211;5.1)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Reilly et al., 2019 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left" colspan="1" rowspan="1">2009&#8211;2015</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">212</td><td align="left" colspan="1" rowspan="1">182</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">22.3 &#177; 19.2<sup>c</sup></td><td align="left" colspan="1" rowspan="1">PMA 30.9 &#177; 4.4<sup>c</sup></td><td align="left" colspan="1" rowspan="1">1.31 &#177; 0.73<sup>c</sup></td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Germovsek et al., 2019 [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left" colspan="1" rowspan="1">2014&#8211;2015</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">102</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1">23.7&#8211;41.9</td><td align="left" colspan="1" rowspan="1">1&#8211;156</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Cristea et al., 2019 [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Netherlands, Portugal</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">319</td><td align="left" colspan="1" rowspan="1">23&#8211;34</td><td align="left" colspan="1" rowspan="1">1&#8211;30</td><td align="left" colspan="1" rowspan="1">PMA 24&#8211;38</td><td align="left" colspan="1" rowspan="1">1.26<sup>b</sup> (0.49&#8211;2.63)</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Back et al., 2019 [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Korea</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">93</td><td align="left" colspan="1" rowspan="1">22.9&#8211;40.3</td><td align="left" colspan="1" rowspan="1">0.7&#8211;562.8</td><td align="left" colspan="1" rowspan="1">PCA 25.6&#8211;110</td><td align="left" colspan="1" rowspan="1">3.2 &#177; 2.6; 0.4&#8211;14.9</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Dao et al., 2019 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left" colspan="1" rowspan="1">2006&#8211;2016</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Switzerland</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">1831</td><td align="left" colspan="1" rowspan="1">405</td><td align="left" colspan="1" rowspan="1">24&#8211;42.1</td><td align="left" colspan="1" rowspan="1">0&#8211;146</td><td align="left" colspan="1" rowspan="1">PMA 28.3&#8211;36.5</td><td align="left" colspan="1" rowspan="1">1.1 (0.46&#8211;5.66)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Mulubwa et al., 2020 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">South Africa</td><td align="left" colspan="1" rowspan="1">Monolix<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">23&#8211;34</td><td align="left" colspan="1" rowspan="1">3&#8211;58</td><td align="left" colspan="1" rowspan="1">PMA 30&#8211;34.7</td><td align="left" colspan="1" rowspan="1">1.48 (0.93&#8211;2.62)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Lee et al., 2021 [<xref ref-type="bibr" rid="CR6">6</xref>]</td><td align="left" colspan="1" rowspan="1">2008&#8211;2017</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Korea</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">900</td><td align="left" colspan="1" rowspan="1">207</td><td align="left" colspan="1" rowspan="1">23.3&#8211;41.5</td><td align="left" colspan="1" rowspan="1">0&#8211;115</td><td align="left" colspan="1" rowspan="1">PMA 24&#8211;48.4</td><td align="left" colspan="1" rowspan="1">1.8 (0.5&#8211;5.9)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Sasano et al., 2021 [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left" colspan="1" rowspan="1">2009&#8211;2018</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">62</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">22.6&#8211;30.3</td><td align="left" colspan="1" rowspan="1">0&#8211;75</td><td align="left" colspan="1" rowspan="1">PMA 23.9&#8211;39.0</td><td align="left" colspan="1" rowspan="1">0.89 (0.45&#8211;1.46)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Jarugula et al., 2022 [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left" colspan="1" rowspan="1">2011&#8211;2018</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Pumas (v1.0.5)</td><td align="left" colspan="1" rowspan="1">2471</td><td align="left" colspan="1" rowspan="1">934</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0&#8211;184</td><td align="left" colspan="1" rowspan="1">PMA 20.89&#8211;66.68</td><td align="left" colspan="1" rowspan="1">3.58 (0.37&#8211;11.88)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Alsultan et al., 2023 [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Arabia Saudi</td><td align="left" colspan="1" rowspan="1">Monolix<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">214</td><td align="left" colspan="1" rowspan="1">162</td><td align="left" colspan="1" rowspan="1">22&#8211;35</td><td align="left" colspan="1" rowspan="1">1&#8211;30</td><td align="left" colspan="1" rowspan="1">PMA 22&#8211;39</td><td align="left" colspan="1" rowspan="1">1.0 &#177; 0.29; (0.46&#8211;1.7)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Chung and Seto, 2023 [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left" colspan="1" rowspan="1">2017&#8211;2021</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Canada</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">442</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">IQR 25.3&#8211;34.9</td><td align="left" colspan="1" rowspan="1">IQR 9&#8211;41.5</td><td align="left" colspan="1" rowspan="1">PMA (IQR) 30.2&#8211;38.5</td><td align="left" colspan="1" rowspan="1">1.71 (IQR 1.02&#8211;2.5)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="12" rowspan="1"><bold>Gentamicin pharmacokinetic models</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Kelman, 1984 [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">82<sup>d</sup></td><td align="left" colspan="1" rowspan="1">43<sup>d</sup></td><td align="left" colspan="1" rowspan="1">26&#8211;39</td><td align="left" colspan="1" rowspan="1">0&#8211;120</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.8&#8211;3.7</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Thomson et al., 1988 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">270</td><td align="left" colspan="1" rowspan="1">113</td><td align="left" colspan="1" rowspan="1">26&#8211;41</td><td align="left" colspan="1" rowspan="1">1&#8211;46</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Dodge et al., 1991 [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left" colspan="1" rowspan="1">1988&#8211;1989</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">NPEM and STS</td><td align="left" colspan="1" rowspan="1">295</td><td align="left" colspan="1" rowspan="1">129</td><td align="left" colspan="1" rowspan="1">28.6 &#177; 2.2</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Izquierdo et al., 1992 [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Spain</td><td align="left" colspan="1" rowspan="1">MULTI2 program</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">97</td><td align="left" colspan="1" rowspan="1">28&#8211;43</td><td align="left" colspan="1" rowspan="1">2&#8211;30</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Jensen et al., 1992 [<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">150</td><td align="left" colspan="1" rowspan="1">25&#8211;43</td><td align="left" colspan="1" rowspan="1">&lt;7</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">2.4<sup>b</sup> (0.62&#8211;4.9)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Rodvold et al., 1993 [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Abbott base Pharmacokinetic System</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">27&#8211;41</td><td align="left" colspan="1" rowspan="1">1&#8211;84</td><td align="left" colspan="1" rowspan="1">PCA 27&#8211;44</td><td align="left" colspan="1" rowspan="1">1.95<sup>b</sup> (0.85&#8211;4.12)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Weber et al., 1993 [<xref ref-type="bibr" rid="CR63">63</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Germany</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">1057</td><td align="left" colspan="1" rowspan="1">469</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">2.34</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Vervelde et al., 1999 [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td align="left" colspan="1" rowspan="1">1996&#8211;1997</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Netherlands</td><td align="left" colspan="1" rowspan="1">NPEM</td><td align="left" colspan="1" rowspan="1">182</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">25&#8211;38</td><td align="left" colspan="1" rowspan="1">1&#8211;24</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1.82 &#177; 0.78; 0.69&#8211;3.9</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Stickland et al., 2001 [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">New Zealand</td><td align="left" colspan="1" rowspan="1">PKBUGS</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PMA 27&#8211;42</td><td align="left" colspan="1" rowspan="1">2.4 &#177; 1.16; 0.54&#8211;5.15</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Touw et al., 2001[<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left" colspan="1" rowspan="1">1996&#8211;2001</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Netherlands</td><td align="left" colspan="1" rowspan="1">MW/PHARM (STS and IT2B)</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">24.7&#8211;37</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Stolk et al., 2002 [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td align="left" colspan="1" rowspan="1">1998&#8211;2000</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Netherlands</td><td align="left" colspan="1" rowspan="1">MW/PHARM (IT2B) and NPEM2</td><td align="left" colspan="1" rowspan="1">725</td><td align="left" colspan="1" rowspan="1">177</td><td align="left" colspan="1" rowspan="1">24&#8211;42.4</td><td align="left" colspan="1" rowspan="1">0&#8211;8</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1.85 &#177; 1.04; 0.57&#8211;4.35</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Botha et al., 2003 [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">South Africa</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">139</td><td align="left" colspan="1" rowspan="1">79</td><td align="left" colspan="1" rowspan="1">27&#8211;40</td><td align="left" colspan="1" rowspan="1">3&#8211;7</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">2.06 &#177; 0.75; 1.95 (0.88&#8211;3.60)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">DiCenzo et al., 2003 [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td align="left" colspan="1" rowspan="1">2000&#8211;2001</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">ADAPT II</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">139</td><td align="left" colspan="1" rowspan="1">23&#8211;42</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1.92 (0.47&#8211;5.00)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Lanao et al., 2004 [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left" colspan="1" rowspan="1">1999&#8211;2003</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Spain</td><td align="left" colspan="1" rowspan="1">WINNONMIX</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">97</td><td align="left" colspan="1" rowspan="1">24&#8211;39</td><td align="left" colspan="1" rowspan="1">1&#8211;26</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1.93 &#177; 0.84 (0.6&#8211;4.2)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Lingvall et al., 2005 [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td align="left" colspan="1" rowspan="1">2000&#8211;2003</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Sweden</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">576</td><td align="left" colspan="1" rowspan="1">277</td><td align="left" colspan="1" rowspan="1">22&#8211;42</td><td align="left" colspan="1" rowspan="1">0&#8211;27</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">2.52 (0.47&#8211;5.08)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Garc&#237;a et al., 2006 [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Spain</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">417</td><td align="left" colspan="1" rowspan="1">200</td><td align="left" colspan="1" rowspan="1">32.2 &#177; 3.0</td><td align="left" colspan="1" rowspan="1">5.5 &#177; 5.4</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1.68 &#177; 0.63</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Nielsen et al., 2009 [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td align="left" colspan="1" rowspan="1">2005&#8211;2006</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Sweden</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">894</td><td align="left" colspan="1" rowspan="1">61</td><td align="left" colspan="1" rowspan="1">23.3&#8211;42.1</td><td align="left" colspan="1" rowspan="1">0&#8211;45</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1.40 (0.50&#8211;5.05)</td><td align="left" colspan="1" rowspan="1">3-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Sherwin et al., 2009 [<xref ref-type="bibr" rid="CR73">73</xref>]</td><td align="left" colspan="1" rowspan="1">1999&#8211;2007</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">New Zealand</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">363</td><td align="left" colspan="1" rowspan="1">116</td><td align="left" colspan="1" rowspan="1">33.8 &#177; 5.4</td><td align="left" colspan="1" rowspan="1">2.7 &#177; 6.8</td><td align="left" colspan="1" rowspan="1">34.2 &#177; 5.6</td><td align="left" colspan="1" rowspan="1">2.3 &#177; 1.2</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Fuchs et al., 2014 [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left" colspan="1" rowspan="1">2006&#8211;2011</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Switzerland</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">3039</td><td align="left" colspan="1" rowspan="1">1449</td><td align="left" colspan="1" rowspan="1">24&#8211;42</td><td align="left" colspan="1" rowspan="1">0&#8211;94</td><td align="left" colspan="1" rowspan="1">PMA 24.2&#8211;42.4</td><td align="left" colspan="1" rowspan="1">2.17 (0.44&#8211;5.51)</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Germovsek et al., 2016 [<xref ref-type="bibr" rid="CR74">74</xref>]</td><td align="left" colspan="1" rowspan="1">2012&#8211;2013</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">1325</td><td align="left" colspan="1" rowspan="1">205</td><td align="left" colspan="1" rowspan="1">23.3&#8211;42.1</td><td align="left" colspan="1" rowspan="1">1&#8211;66</td><td align="left" colspan="1" rowspan="1">PMA 23.3&#8211;43.8</td><td align="left" colspan="1" rowspan="1">2.12 &#177; 0.63</td><td align="left" colspan="1" rowspan="1">3-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Bijleveld et al., 2017 [<xref ref-type="bibr" rid="CR75">75</xref>]</td><td align="left" colspan="1" rowspan="1">2012&#8211;2013</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Netherlands</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">136</td><td align="left" colspan="1" rowspan="1">65</td><td align="left" colspan="1" rowspan="1">25&#8211;42</td><td align="left" colspan="1" rowspan="1">0&#8211;31</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="12" rowspan="1"><bold>Amikacin pharmacokinetic models</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Assael et al., 1982 [<xref ref-type="bibr" rid="CR76">76</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Italy</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">28.5&#8211;42</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Kenyon et al., 1990 [<xref ref-type="bibr" rid="CR77">77</xref>]</td><td align="left" colspan="1" rowspan="1">1987</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Canada</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PCA 26&#8211;36</td><td align="left" colspan="1" rowspan="1">1.38 &#177; 0.47; 0.61&#8211;2.31</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Botha et al., 1998 [<xref ref-type="bibr" rid="CR78">78</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">South Africa</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">106</td><td align="left" colspan="1" rowspan="1">35.1 &#177; 3.6</td><td align="left" colspan="1" rowspan="1">6.3 &#177; 3.3</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Allegaert et al., 2006 [<xref ref-type="bibr" rid="CR79">79</xref>]</td><td align="left" colspan="1" rowspan="1">1999&#8211;2004</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Belgium</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">410</td><td align="left" colspan="1" rowspan="1">205</td><td align="left" colspan="1" rowspan="1">24&#8211;30</td><td align="left" colspan="1" rowspan="1">1&#8211;3</td><td align="left" colspan="1" rowspan="1">PCA 24&#8211;30</td><td align="left" colspan="1" rowspan="1">1.05 (0.48&#8211;1.91)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Allegaert et al., 2007 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left" colspan="1" rowspan="1">2002&#8211;2006</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Belgium</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">564</td><td align="left" colspan="1" rowspan="1">282</td><td align="left" colspan="1" rowspan="1">24&#8211;30</td><td align="left" colspan="1" rowspan="1">1&#8211;3</td><td align="left" colspan="1" rowspan="1">PMA 24&#8211;30</td><td align="left" colspan="1" rowspan="1">0.97 (0.45&#8211;1.98)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Allegaert et al., 2008 [<xref ref-type="bibr" rid="CR80">80</xref>]</td><td align="left" colspan="1" rowspan="1">2005&#8211;2007</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Belgium</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">1862</td><td align="left" colspan="1" rowspan="1">715</td><td align="left" colspan="1" rowspan="1">24&#8211;43</td><td align="left" colspan="1" rowspan="1">1&#8211;30</td><td align="left" colspan="1" rowspan="1">PMA 24&#8211;43</td><td align="left" colspan="1" rowspan="1">1.99 (0.385&#8211;4.780)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Sherwin et al., 2009 [<xref ref-type="bibr" rid="CR81">81</xref>]</td><td align="left" colspan="1" rowspan="1">2003&#8211;2007</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">New Zealand</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">358</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">24&#8211;41</td><td align="left" colspan="1" rowspan="1">3&#8211;64</td><td align="left" colspan="1" rowspan="1">PMA 24.7&#8211;44.0</td><td align="left" colspan="1" rowspan="1">1.03 (0.45&#8211;4.43)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">De Cock et al., 2012 [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">Belgium</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">2186</td><td align="left" colspan="1" rowspan="1">874</td><td align="left" colspan="1" rowspan="1">24&#8211;43</td><td align="left" colspan="1" rowspan="1">1&#8211;30</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">1.82<sup>c</sup> (0.39&#8211;4.78)</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Smits et al., 2015 [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left" colspan="1" rowspan="1">2011&#8211;2012</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Belgium</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">1195</td><td align="left" colspan="1" rowspan="1">579</td><td align="left" colspan="1" rowspan="1">24&#8211;41</td><td align="left" colspan="1" rowspan="1">1&#8211;30</td><td align="left" colspan="1" rowspan="1">PMA 24&#8211;45</td><td align="left" colspan="1" rowspan="1">2.1 (0.42&#8211;5.04)</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Illamola et al., 2016 [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left" colspan="1" rowspan="1">2000&#8211;2006</td><td align="left" colspan="1" rowspan="1">RD</td><td align="left" colspan="1" rowspan="1">France</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">446</td><td align="left" colspan="1" rowspan="1">149</td><td align="left" colspan="1" rowspan="1">24.3&#8211;41</td><td align="left" colspan="1" rowspan="1">1&#8211;86</td><td align="left" colspan="1" rowspan="1">PMA 25&#8211;51.4</td><td align="left" colspan="1" rowspan="1">1.92 (0.50&#8211;4.65)</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Amponsah et al., 2017 [<xref ref-type="bibr" rid="CR82">82</xref>]</td><td align="left" colspan="1" rowspan="1">2013&#8211;2014</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Ghana</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">419</td><td align="left" colspan="1" rowspan="1">247</td><td align="left" colspan="1" rowspan="1">25&#8211;44</td><td align="left" colspan="1" rowspan="1">0&#8211;1</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">2.3 (0.9&#8211;5.2)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Caceres-Guido et al., 2017 [<xref ref-type="bibr" rid="CR83">83</xref>]</td><td align="left" colspan="1" rowspan="1">2003&#8211;2007</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Argentina</td><td align="left" colspan="1" rowspan="1">Monolix<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">28&#8211;40</td><td align="left" colspan="1" rowspan="1">6&#8211;58</td><td align="left" colspan="1" rowspan="1">PMA 29&#8211;43</td><td align="left" colspan="1" rowspan="1">2.65 (1.4&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">1-CMT</td></tr><tr><td align="left" colspan="1" rowspan="1">Severino et al., 2023 [<xref ref-type="bibr" rid="CR84">84</xref>]</td><td align="left" colspan="1" rowspan="1">2019&#8211;2021</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">Chile</td><td align="left" colspan="1" rowspan="1">NONMEM<sup>&#174;</sup></td><td align="left" colspan="1" rowspan="1">329</td><td align="left" colspan="1" rowspan="1">116</td><td align="left" colspan="1" rowspan="1">29&#8211;38</td><td align="left" colspan="1" rowspan="1">10&#8211;41.8</td><td align="left" colspan="1" rowspan="1">PMA 32&#8211;42.4</td><td align="left" colspan="1" rowspan="1">2.8 (1.6&#8211;3.8)</td><td align="left" colspan="1" rowspan="1">2-CMT</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean &#177; standard deviation or median (range) unless otherwise indicated</p><p>Abbreviations: GA, gestational age; ND, no data; PCA, post-conceptional age; PD, prospective data; PMA, postmenstrual age; PNA, postnatal age; RD, retrospective data; wk, week(s); 1-CMT, one-compartment model; 2-CMT, two-compartment model; 3-CMT, three-compartment model</p><p><sup>a</sup>Only included patients from group 1: patients with vancomycin and without indomethacin</p><p><sup>b</sup>Mean value</p><p><sup>c</sup>Weighted averages of the subgroups of the included patients</p><p><sup>d</sup>Only included neonates from Glasgow Hospital (group I)</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec11"><title>Population Pharmacokinetic Analysis</title><sec id="Sec12"><title>Vancomycin</title><p id="Par19">The median values of the pharmacokinetic parameters of vancomycin popPK models are summarized in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Median values of the pharmacokinetic parameters of the vancomycin population pharmacokinetic models calculated for the &#8220;typical&#8221; neonate</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">1-CMT (<italic toggle="yes">n</italic> = 29)</th><th align="left" colspan="4" rowspan="1">2-CMT (<italic toggle="yes">n</italic> = 4)</th></tr><tr><th align="left" colspan="1" rowspan="1">Cl</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub></th><th align="left" colspan="1" rowspan="1">Cl</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">Q</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>0.18 [0.05&#8211;4.33]</p><p> L/h/kg</p></td><td align="left" colspan="1" rowspan="1"><p>1.73 [0.138&#8211;2.81] </p><p>L/kg</p></td><td align="left" colspan="1" rowspan="1"><p>0.198 [0.08&#8211;0.45] </p><p>L/h/kg</p></td><td align="left" colspan="1" rowspan="1"><p>0.387 [0.09&#8211;1.14]</p><p> L/h/kg</p></td><td align="left" colspan="1" rowspan="1"><p>1.32 [0.42&#8211;1.59] </p><p>L/kg</p></td><td align="left" colspan="1" rowspan="1"><p>0.87 [0.08&#8211;2.29] </p><p>L/kg</p></td></tr></tbody></table><table-wrap-foot><p>Data are presented as median (range)</p><p>Abbreviations: Cl, clearance; Q, intercompartmental clearance; Vc volume of distribution of peripheral compartment model; V<sub>d</sub> volume of distribution; Vp, volume of distribution of peripheral compartment; 1-CMT, one-compartment model; 2-CMT, two-compartment model</p></table-wrap-foot></table-wrap></p><p id="Par20">The frequency of covariates included in the popPK model ranged from one to six for CL. WT (83.3%), serum creatinine (Cr) (50.0%), PMA (44.4%), estimated creatinine clearance (ClCr; 13.8%), PNA (13.8%), and GA (11.1%) were the most frequently reported significant predictors of vancomycin CL. In general, vancomycin CL was positively affected by WT, PMA, GA, and PNA and negatively affected by Cr levels. Some models also included PCA, dopamine, concomitant therapy with a nonselective cyclooxygenase inhibitor, artificial ventilation, concomitant therapy with amoxicillin&#8211;clavulanic acid, vancomycin volume of infusion, and urine output as covariates.</p><p id="Par21">The covariates included in vancomycin popPK models for estimating <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> included up to two covariates, although most models only included one (<italic toggle="yes">n</italic> = 30). WT was the most frequently reported significant predictor of <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> among almost all popPK models (91.7%). The model by Kato et al. [<xref ref-type="bibr" rid="CR47">47</xref>] assumed a fixed <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> (1.19 L), like the 2-CMT model of Song et al. [<xref ref-type="bibr" rid="CR48">48</xref>], with fixed <italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub> (1.27 L) and V<sub>p</sub> (2.422 L). The <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> was influenced only by PMA in the model by Silva et al. [<xref ref-type="bibr" rid="CR36">36</xref>]. Two models included concomitant treatment with inotropes or spironolactone as covariates [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p></sec><sec id="Sec13"><title>Gentamicin</title><p id="Par22">The median values of the pharmacokinetic parameters of gentamycin popPK models are summarized in Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Median values of the pharmacokinetic parameters of the gentamycin population pharmacokinetic models calculated for the &#8220;typical&#8221; neonate.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">1-CMT (<italic toggle="yes">n</italic> = 21)</th><th align="left" colspan="4" rowspan="1">2-CMT (<italic toggle="yes">n</italic> = 3)</th><th align="left" colspan="6" rowspan="1">3-CMT (<italic toggle="yes">n</italic> = 2)</th></tr><tr><th align="left" colspan="1" rowspan="1">Cl</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub></th><th align="left" colspan="1" rowspan="1">Cl</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">Q</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">p</italic></sub></th><th align="left" colspan="1" rowspan="1">Cl</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">Q</italic><sub>2</sub></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">Q</italic><sub>3</sub></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">p2</italic></sub></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">p3</italic></sub></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">0.16 (0.05&#8211;2.15) L/h/kg</td><td align="left" colspan="1" rowspan="1">1.435 (0.41&#8211;1.79) L/kg</td><td align="left" colspan="1" rowspan="1">0.19 (0.142&#8211;0.2) L/h/kg</td><td align="left" colspan="1" rowspan="1">0.05 (0.005 &#8211;0.2) L/h/kg</td><td align="left" colspan="1" rowspan="1">1.45 (1.39&#8211;1.60) L/kg</td><td align="left" colspan="1" rowspan="1">0.73 (0.42&#8211;0.77) L/kg</td><td align="left" colspan="1" rowspan="1">0.317 (0.184&#8211; 0.45) L/h/kg</td><td align="left" colspan="1" rowspan="1">0.205 (0.2&#8211;0.21) L/h/kg</td><td align="left" colspan="1" rowspan="1">0.03 (0.025&#8211;0.04) L/h/kg</td><td align="left" colspan="1" rowspan="1">1.17 (1.14&#8211;1.20) L/kg</td><td align="left" colspan="1" rowspan="1">0.92 (0.91&#8211;0.93) L/kg</td><td align="left" colspan="1" rowspan="1">10.78 (6.34&#8211;15.21) L/kg</td></tr></tbody></table><table-wrap-foot><p>Data are presented as median (range)</p><p>Abbreviations: Cl, clearance; <italic toggle="yes">Q</italic>, intercompartmental clearance; <italic toggle="yes">Q</italic><sub>2</sub> and <italic toggle="yes">Q</italic><sub>3</sub>: Intercompartmental clearances between the central and each of the two peripheral compartments; <italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub> volume of distribution of peripheral compartment model; <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> volume of distribution; <italic toggle="yes">V</italic><sub><italic toggle="yes">p</italic></sub>, volume of distribution of peripheral compartment; <italic toggle="yes">V</italic><sub><italic toggle="yes">p2</italic></sub> and <italic toggle="yes">V</italic><sub><italic toggle="yes">p3</italic></sub>: volume of distribution of peripheral compartments; 1-CMT, one-compartment model; 2-CMT, two-compartment model; 3-CMT, three-compartment model</p></table-wrap-foot></table-wrap></p><p id="Par23">The number of covariates included in the popPK models ranged from one to four for CL. Four studies did not report the equations for CL and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>. The covariates most frequently included to estimate gentamicin CL were WT (72.7%), PNA (40.9%), GA (31.8%), Cr (18.2%), PCA (14.2%), and PMA (9.5%). Other covariates also included in some models were Apgar score, sex, birth weight (BW), and ClCr.</p><p id="Par24">The covariates included in gentamicin popPK models for estimating <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> included up to two covariates. WT was reported to be a significant predictor of <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> among 18 popPK models (81.8%). GA (<italic toggle="yes">n</italic> = 5) and sepsis (<italic toggle="yes">n</italic> = 2) were the other covariates also included in the equations for estimating gentamicin <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>.</p></sec><sec id="Sec14"><title>Amikacin</title><p id="Par25">The median values of the pharmacokinetic parameters of amikacin popPK models are summarized in Table <xref rid="Tab4" ref-type="table">4</xref>.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Median values of the pharmacokinetic parameters of the amikacin population pharmacokinetic models calculated for the &#8220;typical&#8221; neonate</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">1-CMT (n = 8)</th><th align="left" colspan="4" rowspan="1">2-CMT (n = 6)</th></tr><tr><th align="left" colspan="1" rowspan="1">Cl</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub></th><th align="left" colspan="1" rowspan="1">Cl</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">Q</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">p</italic></sub></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">0.15 (0.11&#8211;0.304) L/h/kg</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">1.62 [1.37 &#8211; 2.26] L/kg</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.17 (0.13&#8211;0.43) L/h/kg</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">0.15 (0.06&#8211;0.18) L/h/kg</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">1.08 (1.01&#8211;1.40) L/kg</td><td char="&#x2013;" align="char" colspan="1" rowspan="1">1.36 (0.16&#8211;1.44) L/kg</td></tr></tbody></table><table-wrap-foot><p>Data are presented as median (range).</p><p>Abbreviations: Cl, clearance; <italic toggle="yes">Q</italic>, intercompartmental clearance; <italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub> volume of distribution of peripheral compartment model; <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> volume of distribution; <italic toggle="yes">V</italic><sub><italic toggle="yes">p</italic></sub>, volume of distribution of peripheral compartment; 1-CMT, one-compartment model; 2-CMT, two-compartment model.</p></table-wrap-foot></table-wrap></p><p id="Par26">The number of covariates included in the popPK model ranged from one to six for CL. Three studies did not report the equations for CL and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>. The covariates most frequently included to estimate gentamicin CL were WT (66.7%), PMA (41.7%), PNA (25.0%), and Cr (16.7%), which aligns with the study by Match et al. [<xref ref-type="bibr" rid="CR31">31</xref>]. Other covariates also included in some models were sex, concomitant therapy with nonselective cyclooxygenase inhibitors, nonsteroidal anti-inflammatory drug or ibuprofen, intrauterine growth retardation, GA, BW, inotropes, artificial ventilation, shock, sepsis, and ClCr.</p><p id="Par27">Amikacin popPK models for estimating <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> included up to four covariates. WT was reported to be a significant predictor of <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> among nine popPK models (64.3%). The most complex equation for CL and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> was in the study by Allegaert et al. [<xref ref-type="bibr" rid="CR80">80</xref>], which included five and four covariates for estimating CL and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>, respectively.</p><p id="Par28">Allegaert et al. developed three popPK models for amikacin [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. One [<xref ref-type="bibr" rid="CR40">40</xref>] used the same equation for vancomycin and amikacin CL and a correction factor (FCl<sub>amikacin</sub>) for scaling vancomycin to amikacin CL.</p><p id="Par29">The equations for CL and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> derived from popPK models of the included studies are summarized in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>, and the model variability is shown in Table <xref rid="MOESM1" ref-type="media">S1</xref> in the supplementary material. The CL and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> calculated for a &#8220;typical&#8221; neonate of WT 3kg, PNA 30 days, PMA 40 weeks, GA 30 weeks, BW 2 kg, Cr 0.6 mg/dL (53 &#181;mol/L), ClCr 30 ml/min/1.73m<sup>2</sup>, and no other covariates are summarized in Table <xref rid="MOESM2" ref-type="media">S2</xref> in the supplementary material.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Population pharmacokinetic model equations and mean values of pharmacokinetic parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study, year of publication</th><th align="left" colspan="1" rowspan="1">Variables used for CL estimation</th><th align="left" colspan="1" rowspan="1">CL equation</th><th align="left" colspan="1" rowspan="1">Mean CL in L/h/kg</th><th align="left" colspan="1" rowspan="1">Variables used for <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> estimation</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> equation</th><th align="left" colspan="1" rowspan="1">Mean <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> in L/kg</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1"><bold>Vancomycin pharmacokinetic models</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Schaible et al., 1986 [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left" colspan="1" rowspan="1"><p>M1: PCA</p><p>M2: WT, Cr</p></td><td align="left" colspan="1" rowspan="1"><p>M1: CL (L/h) = 0.0224 &#215; PCA &#8722; 0.639</p><p>M2: CL (L/h) = 0.06 &#215; WT + 0.095 &#215; 1/Cr &#8211; 0.141</p></td><td align="left" colspan="1" rowspan="1"><p>M1: 0.129</p><p>M2: 0.069 (for mean weight 2 kg, PCA 40 wks, Cr 0.62 mg/dL)</p></td><td align="left" colspan="1" rowspan="1">M1 and 2: WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.563 &#215; WT + 0.052</td><td align="left" colspan="1" rowspan="1">1.18 (for mean weight 2 kg, PCA 40 wks, Cr)</td></tr><tr><td align="left" colspan="1" rowspan="1">Asbury et al., 1993 [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left" colspan="1" rowspan="1">PCA</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.0281 &#215; PCA &#8211; 0.818</td><td align="left" colspan="1" rowspan="1">0.072<sup>a</sup></td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.557 &#215; WT &#8722; 0.051</td><td align="left" colspan="1" rowspan="1">0.52<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Seay et al., 1994 [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left" colspan="1" rowspan="1">M1 and 2: WT, DA, GA</td><td align="left" colspan="1" rowspan="1"><p>M1: 1-CMT: CL (L/kg/h) = 0.0626 &#215; WT &#215; 0.455<sup>Z1</sup> &#215; 0.656<sup>Z2</sup></p><p>M2: 2-CMT: CL (L/kg/h) = 0.0590 &#215; WT &#215; 0.643<sup>Z1</sup> &#215; 0.46<sup>Z2</sup></p><p>Z1 = 1 if exposed to DA, else Z1= 0, and Z2 = 1 if GA &#8804;32 wks, else Z2 = 0</p><p><italic toggle="yes">Q</italic> (L/h) = 0.0313 &#215;WT</p></td><td align="left" colspan="1" rowspan="1"><p>M1: 1-CMT: 0.063</p><p>M2: 2-CMT: 0.059 (if no DA and GA &gt;32 wks), <italic toggle="yes">Q</italic> = 0.0313</p></td><td align="left" colspan="1" rowspan="1">M1 and 2: WT</td><td align="left" colspan="1" rowspan="1"><p>M1:</p><p>1-CMT: <italic toggle="yes">V</italic> (L) = 0.496 &#215; WT</p><p>M2:</p><p>2-CMT: <italic toggle="yes">V</italic><sub>c</sub> (L) = 0.44 &#215; WT</p><p><italic toggle="yes">V</italic><sub>ss</sub> (L) = 0.764 &#215; WT</p><p><italic toggle="yes">V</italic><sub>ss</sub> = <italic toggle="yes">V</italic><sub>c</sub> + <italic toggle="yes">V</italic><sub>p</sub></p></td><td align="left" colspan="1" rowspan="1"><p>M1:</p><p>1-CMT: <italic toggle="yes">V</italic> = 0.496</p><p>M2:</p><p>2-CMT: <italic toggle="yes">V</italic><sub>c</sub> = 0.44</p><p><italic toggle="yes">V</italic><sub>ss</sub> = 0.764</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Rodvold et al., 1995 [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left" colspan="1" rowspan="1">CLCr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.411 &#215; CLCr + 0.541</td><td align="left" colspan="1" rowspan="1">0.061</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.551 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.551</td></tr><tr><td align="left" colspan="1" rowspan="1">Burstein et al., 1997 [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.038 &#215; WT</p><p><italic toggle="yes">Q</italic> (L/h) = 0.38 &#215; WT</p></td><td align="left" colspan="1" rowspan="1">CL = 0.038, Q = 0.38</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.19 &#215; WT</p><p><italic toggle="yes">V</italic><sub>ss</sub> (L) = 0.48 &#215; WT</p><p><italic toggle="yes">V</italic><sub>ss</sub> (L) = <italic toggle="yes">V</italic><sub>c</sub> + <italic toggle="yes">V</italic><sub>p</sub></p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 0.19</p><p><italic toggle="yes">V</italic><sub>ss</sub> = 0.48</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Silva et al., 1998 [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left" colspan="1" rowspan="1">IND, VENT</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.07 if concomitant treatment with IND or VENT</p><p>CL (L/h) = 0.086 if absence of treatment with IND or VENT</p></td><td align="left" colspan="1" rowspan="1">0.07 presence or 0.086 absence of concomitant treatment with IND or VENT</td><td align="left" colspan="1" rowspan="1">PMA</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic> (L) = 0.562 if PMA &#8804;32 wks</p><p><italic toggle="yes">V</italic> (L) = 0.498 if PMA &gt;32 wks</p></td><td align="left" colspan="1" rowspan="1"><p>0.562 (PMA &#8804;32 wks)</p><p>0.498 (PMA &gt;32 wks)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Grimsley et al., 1999 [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left" colspan="1" rowspan="1">WT, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 3.56 &#215; WT / Cr<sup>b</sup></td><td align="left" colspan="1" rowspan="1">0.11 (for median Cr 49 &#956;mol/L and weight 1.52 kg)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.669 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.669</td></tr><tr><td align="left" colspan="1" rowspan="1">De Hoog et al., 2000 [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.057 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.057</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.43 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.43</td></tr><tr><td align="left" colspan="1" rowspan="1">Capparelli et al., 2001 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left" colspan="1" rowspan="1">WT, Cr, PNA, GA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = WT &#215; (0.028/Cr + 0.000127 &#215; PNA + 0.0123 &#215; GA28) + 0.006</p><p>GA28 = 1 if GA &gt;28 wks; 0 if GA &lt;28 wks</p><p><italic toggle="yes">Q</italic> (L/h) = 0.0334 &#215; WT</p></td><td align="left" colspan="1" rowspan="1">CL = 0.066, Q = 0.0334</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.666 &#215; <italic toggle="yes">V</italic><sub>ss</sub></p><p><italic toggle="yes">V</italic><sub>ss</sub> (L) = 0.793 &#215; WT + 0.01</p><p><italic toggle="yes">V</italic><sub>ss</sub> (L) = <italic toggle="yes">V</italic><sub>c</sub> + <italic toggle="yes">V</italic><sub>p</sub></p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>ss</sub> = 0.793</p><p><italic toggle="yes">V</italic><sub>c</sub> = 0.528</p><p><italic toggle="yes">V</italic><sub>p</sub> = 0.265</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Kimura et al., 2004 [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left" colspan="1" rowspan="1">WT, Cr</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.025 &#215; WT/Cr for PCA &lt;34 wks</p><p>CL (L/h) = 0.0323 &#215; WT/Cr for PCA &#8805;34 wks</p></td><td align="left" colspan="1" rowspan="1">0.075 (for median weight 1.38 kg, Cr 0.6 mg/dL and PCA 37 wks)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.66 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.66</td></tr><tr><td align="left" colspan="1" rowspan="1">Allegaert et al., 2007 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, FNCOX, CLCr, Cr, GA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 1.58 &#215; (WT/70)<sup>0.75</sup> &#215; e<sup>[0.0456&#215;(PMA&#8722;30)]</sup> &#215; RF &#215; FNCOX &#215; FSGA</p><p>RF = RF standardized to CLCr 6 L/h/70 kg in a 40-year-old male assuming a CPR of 516 &#181;mol/h calculated as CPR (&#956;mol/h) = 516 &#215; e<sup>(Kage&#215; ((PMA&#8722;30)/52&#8722;40))</sup> (Kage = 0.00766) and CLCr (L/h) = CPR/Cr</p><p>FNCOX = 0.795 if given nonselective COX inhibitor (scaling factor)</p><p>FSGA = 0.838 for scaling SGA</p></td><td align="left" colspan="1" rowspan="1">0.079 (for mean weight 1.3 kg, 30 wks PMA and appropriate for GA)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 39.3 &#215; (WT/70)</td><td align="left" colspan="1" rowspan="1">0.730 (for mean weight 1.3 kg, 30 wks PMA and appropriate for GA)</td></tr><tr><td align="left" colspan="1" rowspan="1">Anderson et al., 2007 [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, CLCr, Cr, VENT</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 2.19 &#215; (WT/70)<sup>0.75</sup> &#215; [1 + 0.0216 &#215; (PMA &#8722; 40)] &#215; RF &#215; Fventilation &#215; Vent)</p><p>Fventilation = 0.942 if positive pressure for VENT</p><p>Vent = 1 if VENT and 0 if absent</p><p>RF = RF standardized to CLCr 6 L/h/70kg in a 40-year-old person with a serum Cr 85.947 &#956;mol/L, calculated as CPR (&#956;mol/h) = 516 &#215; e<sup>(Kage&#215; ((PMA&#8722;40)/52&#8722;40))</sup> (Kage = 0.00789) and CLCr (L/h)</p></td><td align="left" colspan="1" rowspan="1">0.049 (for mean weight 1.3 kg, 34 wks PMA and no VENT)</td><td align="left" colspan="1" rowspan="1">WT, INO</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic> (L) = 39.0 &#215; (WT/70) &#215; Finotrope &#215; Inot</p><p>Finotrope = 1.18 if use of INO</p><p>Inot = 1 if INO present, 0 if absent</p></td><td align="left" colspan="1" rowspan="1">0.724 (for mean weight 1.3 kg, 34 wks PMA and no artificial ventilation)</td></tr><tr><td align="left" colspan="1" rowspan="1">Marqu&#233;s-Mi&#241;ana et al., 2010 [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, AMX</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.00192 &#215; PMA &#215; WT &#215; (1 + 0.65 &#215; AMX)</p><p>AMX = 1 if co-therapy with AMX; 0 if absent</p></td><td align="left" colspan="1" rowspan="1">0.066</td><td align="left" colspan="1" rowspan="1">WT, SPI</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = (0.572 &#215; (1 &#8722; 0.344 &#215; SPI)) &#215; WT</td><td align="left" colspan="1" rowspan="1">0.572</td></tr><tr><td align="left" colspan="1" rowspan="1">Lo et al., 2010 [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left" colspan="1" rowspan="1">WT, GA, PMA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 1.0 &#215; (WT/70)<sup>0.75</sup> &#215; (PMA/30)<sup>3.16</sup> &#215; [0.83 &#215; GA + 1.03 &#215; (1 &#8722; GA)]</p><p>GA = 1 for SGA infants and 0 for appropriate-for-GA infants</p></td><td align="left" colspan="1" rowspan="1">0.052</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 36.6 &#215; (WT/70)</td><td align="left" colspan="1" rowspan="1">0.523</td></tr><tr><td align="left" colspan="1" rowspan="1">Mehrotra et al., 2012 [<xref ref-type="bibr" rid="CR85">85</xref>]</td><td align="left" colspan="1" rowspan="1">WT, Cr, PMA</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.18 &#215; (WT/2.5)<sup>0.75</sup> &#215; (0.42/Cr)<sup>0.7</sup> &#215; (PMA/37)<sup>1.4</sup></td><td align="left" colspan="1" rowspan="1">0.14 (for mean weight 2.5 kg, Cr 0.6 mg/dL and PMA 37 wks)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 1.7 &#215; (WT/2.5)</td><td align="left" colspan="1" rowspan="1">1.7 (for mean weight 2.5 kg, Cr 0.6 mg/dL and PMA 37 wks)</td></tr><tr><td align="left" colspan="1" rowspan="1">Zhao et al., 2013 [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left" colspan="1" rowspan="1">WT, BW, PNA, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.0571 &#215; (WT/1.416)<sup>0.513</sup> &#215; (BW/1.010)<sup>0.599</sup> &#215; (1 + 0.282 &#215; PNA/17) &#215; [1/(Cr<sup>b</sup>/42)<sup>0.525</sup>]</td><td align="left" colspan="1" rowspan="1">0.073 (for median weight 1.41 kg, BW 1.01 kg, PNA 17 days, Cr 42 &#956;mol/L)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.791 &#215; (WT/1.416)<sup>0.898</sup></td><td align="left" colspan="1" rowspan="1">0.791 (for median weight 1.41 kg, BW 1.01 kg, PNA 17 days, Cr 42 &#956;mol/L)</td></tr><tr><td align="left" colspan="1" rowspan="1">Frymoyer et al., 2014 [<xref ref-type="bibr" rid="CR86">86</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.345 &#215; (WT/2.9)<sup>0.75</sup> &#215; [1/(1 + (PMA/34.8)<sup>-4.53</sup>] &#215; (1/Cr)<sup>0.267</sup></td><td align="left" colspan="1" rowspan="1">0.095</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 1.75 &#215; (WT/2.9)</td><td align="left" colspan="1" rowspan="1">0.603</td></tr><tr><td align="left" colspan="1" rowspan="1">Bhongsatiern et al., 2015 [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left" colspan="1" rowspan="1">WT, CLCr, PMA</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.095 &#215; (WT/1.5)<sup>0.585</sup> &#215; (CLCr/36)<sup>0.720</sup> &#215; (PMA/33)</td><td align="left" colspan="1" rowspan="1">0.068</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.905 &#215; (WT/1.5)</td><td align="left" colspan="1" rowspan="1">0.62</td></tr><tr><td align="left" colspan="1" rowspan="1">Kato et al., 2017 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left" colspan="1" rowspan="1">Cr, volume of infusion</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.054 &#215; (Cr/0.59)<sup>-0.80</sup> &#215; (V<sub>infusion</sub>/159.3)<sup>0.98</sup></td><td align="left" colspan="1" rowspan="1">0.054 (for median weight 0.93kg, Cr 0.59 mg/dL and V<sub>infusion</sub> 159.3mL)</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 1.19</td><td align="left" colspan="1" rowspan="1">1.28 (for median weight 0.93 kg, Cr 0.59 mg/dL and <italic toggle="yes">V</italic><sub>infusion</sub> 159.3 mL</td></tr><tr><td align="left" colspan="1" rowspan="1">Song et al., 2017 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left" colspan="1" rowspan="1">BW, PNA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.42 &#215; (BW/3.22)<sup>0.888</sup> &#215; (PNA/29)<sup>0.449</sup></p><p><italic toggle="yes">Q</italic> (L/h) = 1.161</p></td><td align="left" colspan="1" rowspan="1">CL = 0.106, <italic toggle="yes">Q</italic> = 0.294</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 1.27</p><p><italic toggle="yes">V</italic><sub>p</sub> (L) = 2.422</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 0.32</p><p><italic toggle="yes">V</italic><sub>p</sub> = 0.613</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Tseng et al., 2018 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.0519 &#215; WT<sup>0.75</sup> &#215; (PMA/30.1)<sup>2.4</sup> &#215; (43/Cr<sup>b</sup>)<sup>0.246</sup></td><td align="left" colspan="1" rowspan="1">0.052</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.498 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.498</td></tr><tr><td align="left" colspan="1" rowspan="1">Li et al., 2018 [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left" colspan="1" rowspan="1">WT, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.309 &#215; (WT/2.9)<sup>1.55</sup> &#215; (23.3/Cr<sup>b</sup>)<sup>0.337</sup></td><td align="left" colspan="1" rowspan="1">0.309 (for mean weight 2.9 kg, Cr 23.3 &#956;mol/L)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 2.63 &#215; (WT/2.9)<sup>1.05</sup></td><td align="left" colspan="1" rowspan="1">2.63 (for mean weight 2.9 kg, Cr 23.3 &#956;mol/L)</td></tr><tr><td align="left" colspan="1" rowspan="1">Chen et al., 2018 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 4.87 &#215; (WT/70)<sup>0.75</sup> &#215; [PMA<sup>4.61</sup>/(PMA<sup>4.61</sup> + 34.5<sup>4.61</sup>)] &#215; (Cr/0.28)<sup>-0.221</sup></td><td align="left" colspan="1" rowspan="1">0.103</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 40.7 &#215; (WT/70)</td><td align="left" colspan="1" rowspan="1">0.581</td></tr><tr><td align="left" colspan="1" rowspan="1">Reilly et al., 2019 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PNA, Urine output</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.0558 &#215; WT &#215; (PMA/30)<sup>1.26</sup> &#215; (PNA/18)<sup>0.104</sup> &#215; (urine output/3.8)<sup>0.505</sup></td><td align="left" colspan="1" rowspan="1">0.056</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.491 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.491</td></tr><tr><td align="left" colspan="1" rowspan="1">Germovsek et al., 2019 [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 5.7 &#215; (WT/70 )<sup>0.632</sup> &#215; [PMA<sup>3.4</sup>/(PMA<sup>3.4</sup> + 47.7<sup>3.4</sup>)]</td><td align="left" colspan="1" rowspan="1">0.081</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 39.3 &#215; (WT/70)</td><td align="left" colspan="1" rowspan="1">0.561</td></tr><tr><td align="left" colspan="1" rowspan="1">Cristea et al., 2019 [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PNA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.053 &#215; (WT/1.76)<sup>1.34</sup> &#215; (1 + (0.213 &#215; (PNA/2)) &#215; Fibu &#215; Findo Fibu = 0.838 if concurrent use of IBU</p><p>Findo = 0.447 if concurrent use of IND</p><p><italic toggle="yes">Q</italic> (L/h) = 0.904 &#215; CL</p></td><td align="left" colspan="1" rowspan="1">CL = 0.138, Q = 0.124 (for mean weight 1.76 kg, PNA 15 days, no IND and no IBU)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.913 &#215; (WT/1.75)<sup>0.919</sup></p><p><italic toggle="yes">V</italic><sub>c</sub> = <italic toggle="yes">V</italic><sub>p</sub></p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 0.913</p><p><italic toggle="yes">V</italic><sub>p</sub> = 0.913</p><p>(for mean weight 1.76 kg)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Back et al., 2019 [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 69.4 &#215; (WT/70)<sup>0.75</sup> &#215; [PMA<sup>3.68</sup>/(PMA<sup>3.68</sup> + 33.3<sup>3.68</sup>)]</td><td align="left" colspan="1" rowspan="1">1.46 (for mean weight 3.2 kg and PMA 41 weeks)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 3.23 &#215; (WT/70)</td><td align="left" colspan="1" rowspan="1">0.148 (for mean weight 3.2 kg)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dao et al., 2020 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.273 &#215; WT<sup>0.438</sup> &#215; [(54/Cr<sup>b</sup>)<sup>0.473</sup>] &#215; [PMA<sup>3.54</sup>/(PMA<sup>3.54</sup> + 46.4<sup>3.54</sup>)]</td><td align="left" colspan="1" rowspan="1">0.060 (for median weight 1.1 kg, PMA 32 wks and Cr 54 &#956;mol/L)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.628 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.571 (for median weight 1.1 kg, PMA 32 wks and Cr 54 &#956;mol/L)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mulubwa et al., 2020 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.102 &#215; (WT/1.48)<sup>0.75</sup></td><td align="left" colspan="1" rowspan="1">0.102 (for mean weight 1.48 kg)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.884 &#215; (WT/1.48)</td><td align="left" colspan="1" rowspan="1">0.884 (for mean weight 1.48 kg)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lee et al., 2021 [<xref ref-type="bibr" rid="CR6">6</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, CLCr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 2.09 &#215; (WT/70)<sup>0.75</sup> &#215; (PMA/31.7)<sup>0.795</sup> &#215; (CLCr/50.3)<sup>0.741</sup></td><td align="left" colspan="1" rowspan="1">0.086</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 45.6 &#215; (WT/70)</td><td align="left" colspan="1" rowspan="1">0.651</td></tr><tr><td align="left" colspan="1" rowspan="1">Sasano et al., 2021 [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left" colspan="1" rowspan="1">WT, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.056 &#215; (WT/0.887)<sup>0.75</sup> &#215; (0.35/Cr)<sup>0.539</sup></td><td align="left" colspan="1" rowspan="1">0.056</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.827 &#215; (WT/0.887)</td><td align="left" colspan="1" rowspan="1">0.827</td></tr><tr><td align="left" colspan="1" rowspan="1">Jarugula et al., 2022 [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left" colspan="1" rowspan="1">WT, Cr, PMA</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.237 &#215; (WT/3.5)<sup>0.75</sup> &#215; (0.45/Cr)<sup>0.87</sup> &#215; (PMA/42)<sup>0.81</sup></td><td align="left" colspan="1" rowspan="1">0.237</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 2.98 &#215; (WT/3.5)</td><td align="left" colspan="1" rowspan="1">2.98</td></tr><tr><td align="left" colspan="1" rowspan="1">Alsultan et al., 2023 [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.09 &#215; (WT/0.93)<sup>0.75</sup> &#215; (0.6/Cr)<sup>0.48</sup> &#215; [PMA<sup>4.42</sup>/(PMA<sup>4.42</sup> + 26.3<sup>4.42</sup>)]</td><td align="left" colspan="1" rowspan="1">0.09 (for mean weight 0.93 kg, Cr 0.6 mg/dL and PMA 29 wks)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.81 &#215; (WT/0.93)</td><td align="left" colspan="1" rowspan="1">0.81 (for mean weight 0.93 kg, Cr 0.6 mg/dL and PMA 29 wks)</td></tr><tr><td align="left" colspan="1" rowspan="1">Chung et al., 2023 [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, Cr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 13.9 &#215; (WT/70) &#215; [PMA<sup>0.739</sup>/(PMA<sup>0.739</sup> + 47.7<sup>0.739</sup>)] &#215; (Cr<sup>b</sup>/34)<sup>-0.653</sup></td><td align="left" colspan="1" rowspan="1">0.088</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 65.5 &#215; (WT/70)</td><td align="left" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Gentamycin pharmacokinetic models</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Kelman et al., 1984 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left" colspan="1" rowspan="1"><p>M1: WT, PNA, Cr</p><p>M2: WT, Cr</p></td><td align="left" colspan="1" rowspan="1"><p>M1: CL (L/h) = 0.057 &#215; WT + 0.00074 &#215; PNA &#8722; 0.00019 &#215; Cr<sup>b</sup></p><p>M2: CL (L/h) = 0.063 &#215; WT &#8722; 0.00019 &#215; Cr<sup>b</sup></p></td><td align="left" colspan="1" rowspan="1"><p>M1: 0.057</p><p>M2: 0.063</p></td><td align="left" colspan="1" rowspan="1">M1 and 2: WT</td><td align="left" colspan="1" rowspan="1">M1 and 2: <italic toggle="yes">V</italic> (L) = 0.46 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.46</td></tr><tr><td align="left" colspan="1" rowspan="1">Thomson et al., 1988 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left" colspan="1" rowspan="1"><p>M1: WT, Cr, AP</p><p>M2: PCA, AP</p></td><td align="left" colspan="1" rowspan="1"><p>M1: CL (L/h) = 0.055 &#215; WT &#8722; 0.00013 &#215; Cr<sup>b</sup> &#215; (0.86 if AP &lt; 7)</p><p>M2: CL (L/h/kg) = 0.053 &#215; (0.83 if PCA &lt;34 wks) &#215; (0.82 if AP &lt; 7)</p></td><td align="left" colspan="1" rowspan="1">0.053 if PCA &gt;34 wks and AP &#8805;7; 0.044 if PCA &#8804;34 wks and AP &lt;7; 0.036 if PCA &#8804;34 wks and AP &lt;7</td><td align="left" colspan="1" rowspan="1">M1 and 2: WT</td><td align="left" colspan="1" rowspan="1">M1 and 2: <italic toggle="yes">V</italic> (L) = 0.47 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.47</td></tr><tr><td align="left" colspan="1" rowspan="1">Dodge et al., 1991[<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.046 if GA &#8804;31 wks, 0.094 if GA 31&#8211;34 wks</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1"><p>0.703 &#8211; 0.767 if GA &#8804;31 wks</p><p>0.643&#8211;0.653 if GA 31&#8722;34 wks</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Izquierdo et al., 1992 [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left" colspan="1" rowspan="1"><p>M1: WT, GA, PNA</p><p>M2: WT, PNA, PCA</p><p>Premature pts:</p><p>PCA, WT</p></td><td align="left" colspan="1" rowspan="1"><p>Overall population (&gt;38 wks):</p><p>M1: CL (L/h) = &#8722;0.0958 + 0.0025 &#215; GA + 0.0024 &#215; PNA + 0.0630 &#215; WT</p><p>M2: CL (L/h) = &#8722;0.0896 + 0.0022 &#215; PCA + 0.0022 &#215; PNA + 0.0647 &#215; WT Premature pts (28&#8211;38 GA):</p><p>CL (L/h) = &#8722;0.2310 + 0.0070 &#215; PCA + 0.0612 &#215; WT</p></td><td align="left" colspan="1" rowspan="1">0.069<sup>c</sup></td><td align="left" colspan="1" rowspan="1">All models: WT</td><td align="left" colspan="1" rowspan="1"><p>Overall population (&gt;38 wks):</p><p><italic toggle="yes">V</italic> (L) = 0.1821 + 0.4799 &#215; WT</p><p><italic toggle="yes">V</italic> (L) = 0.6422 &#215; WT<sup>0.8466&#215; (8.42&#215;10-7)</sup></p><p>Premature pts (28 &#8722; 38 GA):</p><p><italic toggle="yes">V</italic> (L) = 0.4086 + 0.3763 &#215; WT</p><p><italic toggle="yes">V</italic> (L) = 0.7517 &#215; WT<sup>0.6483&#215; (3.03&#215;10-4)</sup></p></td><td align="left" colspan="1" rowspan="1">0.547<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Jensen et al., 1992 [<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.120 &#215; (WT/2.4)<sup>1.36</sup></td><td align="left" colspan="1" rowspan="1">0.05</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.429 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.429</td></tr><tr><td align="left" colspan="1" rowspan="1">Rodvold et al., 1993 [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left" colspan="1" rowspan="1">CLCr</td><td align="left" colspan="1" rowspan="1">CL (L/h) = (0.0604 &#215; CLCr) + 0.333</td><td align="left" colspan="1" rowspan="1">0.022</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.56 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.56</td></tr><tr><td align="left" colspan="1" rowspan="1">Weber et al., 1993 [<xref ref-type="bibr" rid="CR63">63</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.0534</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.66</td></tr><tr><td align="left" colspan="1" rowspan="1">Vervelde et al., 1999 [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.059</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.70</td></tr><tr><td align="left" colspan="1" rowspan="1">Stickland et al., 2001 [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.046 (for mean weight 2.4 kg)</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.46 (for mean weight 2.4 kg)</td></tr><tr><td align="left" colspan="1" rowspan="1">Touw et al., 2001 [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left" colspan="1" rowspan="1"><p>M1: WT</p><p>M2: GA</p></td><td align="left" colspan="1" rowspan="1"><p>M1: CL (L/h) = &#8722;0.0342 + 0.0655 &#215; WT</p><p>M2: CL (L/h) = &#8722;0.259 + 0.0106 &#215; GA</p></td><td align="left" colspan="1" rowspan="1">0.0387 (It2B modeling) &#8722; 0.0404 (STS modeling)</td><td align="left" colspan="1" rowspan="1">WT, GA</td><td align="left" colspan="1" rowspan="1"><p>M1: <italic toggle="yes">V</italic> (L) = &#8722;0.034 + 0.647 &#215; WT</p><p>M2: <italic toggle="yes">V</italic> (L) = &#8722;2.39 + 0.109 &#215; GA</p></td><td align="left" colspan="1" rowspan="1">0.586 (It2B modeling) &#8722; 0.623 (STS modeling)</td></tr><tr><td align="left" colspan="1" rowspan="1">Stolk et al., 2002 [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">WT, GA</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 1.076 + 0.666 &#215; WT &#8722; 0.0372 &#215; GA</td><td align="left" colspan="1" rowspan="1">0.631<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Botha et al., 2003 [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left" colspan="1" rowspan="1">WT, GA, sex (P)</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.001 &#215; WT &#215; GA &#215; P</p><p>P = 1.2 for girls and 1 for boys</p></td><td align="left" colspan="1" rowspan="1">0.042</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.472 &#215; WT</td><td align="left" colspan="1" rowspan="1">0.472</td></tr><tr><td align="left" colspan="1" rowspan="1">DiCenzo et al., 2003 [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td align="left" colspan="1" rowspan="1">GA, BW</td><td align="left" colspan="1" rowspan="1">CL (L/h) = (0.00504 + [0.00108 &#215; GA]) &#215; BW</td><td align="left" colspan="1" rowspan="1">0.076 (for median BW 1.92 kg and GA 32 wks)</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.136 (for median BW 1.92 kg)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lanao et al., 2004 [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PNA</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.032 &#215; WT<sup>1.482</sup> + 0.0024 &#215; PNA</td><td align="left" colspan="1" rowspan="1">0.032</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.636 &#215; WT<sup>0.852</sup></td><td align="left" colspan="1" rowspan="1">0.636</td></tr><tr><td align="left" colspan="1" rowspan="1">Lingvall et al., 2005 [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td align="left" colspan="1" rowspan="1">GA, AP</td><td align="left" colspan="1" rowspan="1">CL (L/h/kg) = 0.0177 + 0.00147 &#215; (GA &#8722;20) + 0.000635 &#215; AP</td><td align="left" colspan="1" rowspan="1">0.046</td><td align="left" colspan="1" rowspan="1">Sepsis</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L/kg) = 0.483 + 0.0656 &#215; sepsis</td><td align="left" colspan="1" rowspan="1">0.483</td></tr><tr><td align="left" colspan="1" rowspan="1">Garc&#237;a et al., 2006 [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PNA, CLCr</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h/kg) = (0.00582 &#215; WT + 0.00106 &#215; CLCr) &#215; WT + 0.00131 &#215; PNA</p><p><italic toggle="yes">Q</italic> (L/h) = 0.0157</p></td><td align="left" colspan="1" rowspan="1">CL = 0.078, <italic toggle="yes">Q</italic> = 0.009 (for mean weight 1.69 kg and PNA 5.49 days)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.484 &#215; WT</p><p><italic toggle="yes">V</italic><sub>p</sub> (L) = 1.25</p></td><td align="left" colspan="1" rowspan="1"><p>V<sub>c</sub> = 0.813</p><p>V<sub>p</sub> = 0.74</p><p>(for mean weight 1.69 kg and PNA 5.49 days)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Nielsen et al., 2009 [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td align="left" colspan="1" rowspan="1">WT, GA, PNA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.00999 &#215; WT<sup>0.75</sup> &#215; [1 + 0.0862 &#215; (GA &#8722; 29)] &#215; (1+ PNA<sup>0.548</sup>) <italic toggle="yes">Q</italic><sub>2</sub> (L/h) = 0.0939 &#215; WT<sup>0.75</sup></p><p><italic toggle="yes">Q</italic><sub>3</sub> (L/h) = 0.0173 &#215; WT<sup>0.75</sup></p></td><td align="left" colspan="1" rowspan="1">CL = 0.026, <italic toggle="yes">Q</italic><sub>2</sub> = 0.121, <italic toggle="yes">Q</italic><sub>3</sub> = 0.022 (for mean weight 1.4 kg, GA 29 days and PNA 1 day)</td><td align="left" colspan="1" rowspan="1">WT, GA</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.405 &#215; WT &#215; [(1 &#8722; 0.0116) &#215; (GA &#8722; 29)]</p><p><italic toggle="yes">V</italic><sub>p2</sub> = 0.310 &#215; WT</p><p><italic toggle="yes">V</italic><sub>p3</sub> = 5.07 &#215; WT</p></td><td align="left" colspan="1" rowspan="1"><p>V<sub>c</sub> = 0.567</p><p>V<sub>p2</sub> = 0.434</p><p>V<sub>p3</sub> = 7.1</p><p>(for mean weight 1.4 kg, GA 29 days and PNA 1 day)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Sherwin et al., 2009 [<xref ref-type="bibr" rid="CR73">73</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PNA</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.097 &#215; (WT/2)<sup>1.3</sup> &#215; (PNA/7)<sup>0.29</sup></td><td align="left" colspan="1" rowspan="1">0.037 (for mean weight 2.3 kg, PNA 3 days)</td><td align="left" colspan="1" rowspan="1">WT, sepsis</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 1.07 &#215; (WT/2)<sup>0.8</sup> + (sepsis &#215; 0.13) Sepsis = 1 if confirmed sepsis, 0 if absent</td><td align="left" colspan="1" rowspan="1">0.687 (for mean weight 2.3kg and no sepsis)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fuchs et al., 2014 [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left" colspan="1" rowspan="1">WT, GA, PNA, DA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.089 &#215; (WT/2.17)<sup>0.75</sup> &#215; [1 + 1.870 &#215; ((GA &#8722; 34)/34)] &#215; [1 + 0.054 &#215; (PNA &#8722; 1)] &#215; (1 &#8722; 0.120)</p><p><italic toggle="yes">Q</italic> (L/h) = 0.157 &#215; (WT/2.17)<sup>0.75</sup></p></td><td align="left" colspan="1" rowspan="1">CL = 0.089, <italic toggle="yes">Q</italic> = 0.157 (for mean weight 2.17 kg, GA 34 wks and PNA 1 day)</td><td align="left" colspan="1" rowspan="1">WT, GA</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.908 &#215; (WT/2.17) &#215; [1&#8722; 0.922 &#215; ((GA &#8722; 34)/34)]</p><p><italic toggle="yes">V</italic><sub>p</sub> (L) = 0.560 &#215; (WT/2.17)</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 0.908</p><p><italic toggle="yes">V</italic><sub>p</sub> = 0.560</p><p>(for mean weight 2.17 kg, GA 34 wks and PNA 1 day)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Germovsek et al., 2016 [<xref ref-type="bibr" rid="CR74">74</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, Cr, PNA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h/70kg) = 6.21 &#215; (WT/70)<sup>0.632</sup> &#215; [PMA<sup>3.33</sup>/(PMA<sup>3.33</sup> + 55.4<sup>3.33</sup>) &#215; (Cr/TSCr)<sup>&#8722;0.13</sup> &#215; [PNA/(1.70 + PNA)] TSCr = 2.849 &#215; PMA + 166.48</p><p><italic toggle="yes">Q</italic><sub>2</sub> (L/h /70kg) = 2.15 &#215; (WT/70)<sup>0.75</sup></p><p><italic toggle="yes">Q</italic><sub>3</sub> (L/h /70kg) = 0.27 &#215; (WT/70)<sup>0.75</sup></p></td><td align="left" colspan="1" rowspan="1">CL = 0.036, <italic toggle="yes">Q</italic><sub>2</sub> = 0.074, <italic toggle="yes">Q</italic><sub>3</sub> = 0.009</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 26.5 &#215; (WT/70)</p><p><italic toggle="yes">V</italic><sub>p2</sub> (L) = 21.1 &#215; (WT/70)</p><p><italic toggle="yes">V</italic><sub>p3</sub> (L) = 148 &#215; (WT/70)</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 0.379</p><p><italic toggle="yes">V</italic><sub>p2</sub> = 0.303</p><p><italic toggle="yes">V</italic><sub>p3</sub> = 2.114</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Bijleveld et al., 2017 [<xref ref-type="bibr" rid="CR75">75</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.0413 &#215; WT<sup>0.75</sup> &#215; (PMA/32.14)<sup>1.89</sup></p><p>Q (L/h) = 0.0236 &#215; WT<sup>0.75</sup></p></td><td align="left" colspan="1" rowspan="1">CL = 0.066, <italic toggle="yes">Q</italic> = 0.037 (for mean weight 1.85 kg, PMA 32 wks)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.534 &#215; WT</p><p><italic toggle="yes">V</italic><sub>p</sub> (L) = 0.244 &#215; WT</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 0.99</p><p><italic toggle="yes">V</italic><sub>p</sub> = 0.45</p><p>(for mean weight 1.85 kg, PMA 32 wks)</p></td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Amikacin pharmacokinetic models</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Assael et al., 1982 [<xref ref-type="bibr" rid="CR76">76</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.0516</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 0.49</p><p><italic toggle="yes">V</italic><sub>ss</sub> = 0.80</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Kenyon et al., 1990 [<xref ref-type="bibr" rid="CR77">77</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.0504</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.57</td></tr><tr><td align="left" colspan="1" rowspan="1">Botha et al., 1998 [<xref ref-type="bibr" rid="CR78">78</xref>]</td><td align="left" colspan="1" rowspan="1">WT, sex (P)</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.031 &#215; WT<sup>1.45</sup> &#215; P</p><p>P = 1.28 for girls; 1.0 for boys</p></td><td align="left" colspan="1" rowspan="1">0.048</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.316 &#215; WT<sup>1.44</sup></td><td align="left" colspan="1" rowspan="1">0.434</td></tr><tr><td align="left" colspan="1" rowspan="1">Allegaert et al., 2006 [<xref ref-type="bibr" rid="CR79">79</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PCA, NSAID</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h/70kg) = [0.486 &#215; (WT/70)<sup>0.75</sup>] &#215; e<sup>[0.11&#215; (PCA&#8722;24) &#215;FNSAID]</sup></p><p>FNSAID = 0.788 if a premature neonate is given NSAID</p></td><td align="left" colspan="1" rowspan="1">0.028 (for mean weight 1 kg, PCA 27 wks, and no NSAID)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 40.2 &#215; (WT/70)</td><td align="left" colspan="1" rowspan="1">0.574</td></tr><tr><td align="left" colspan="1" rowspan="1">Allegaert et al., 2007 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, FNCOX, CLCr, Cr, GA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 1.58 &#215; (WT/70)<sup>0.75</sup> &#215; e<sup>[0.0456&#215;(PMA&#8722;30)]</sup> &#215; RF &#215; FNCOX &#215; FCl<sub>amikacin</sub> &#215; FSGA</p><p>RF = CLCr/(6 L&#8725;h&#8725;70kg)</p><p>FNCOX = 0.795 if given nonselective COX inhibitor (scaling factor)</p><p>FCl<sub>amikacin</sub> = 0.567 for scaling amikacin CL relative to that of vancomycin FSGA = 0.838 for scaling SGA</p></td><td align="left" colspan="1" rowspan="1"><p>0.040 (for mean weight 1 kg, 28 wks PMA and appropriate for</p><p>GA)</p></td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 39.3 &#215; (WT/70)</td><td align="left" colspan="1" rowspan="1">0.561 (for mean weight 1 kg, 28 wks PMA and appropriate for GA)</td></tr><tr><td align="left" colspan="1" rowspan="1">Allegaert et al., 2008 [<xref ref-type="bibr" rid="CR80">80</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, VENT, INO, SGA</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h/70kg) = 1.49 &#215; (WT/70)<sup>0.75</sup> &#215; [1+ 0.032 &#215; (PMA &#8722; 40)] &#215; RF &#215; Fventilation &#215; VENT &#215; Finotrope &#215; INO &#215; Fiugr &#215; SGA)</p><p>Finotrope = 0.945 applied if use of INO</p><p>Fventilation = 0.977 applied if use of positive pressure VENT</p><p>Fiugr = 0.872 applied if intrauterine growth retardation</p><p>INO, VENT, and SGA have a value of 1 if present, 0 if absent.</p><p>RF = RF standardized to CLCr 6 L/h/70 kg in a 40-year-old person with a serum Cr of 85.947 &#956;mol/L, calculated as CPR (&#956;mol/h) = 516 &#215; e<sup>(Kage&#215; ((PMA&#8722;30)/52&#8722;40))</sup> (Kage = 0.00344) and CLCr (L/h) = CPR/Cr</p></td><td align="left" colspan="1" rowspan="1">0.0497 (for mean weight 1 kg, PMA 34 wks, PNA 1 day, no INO, no VENT)</td><td align="left" colspan="1" rowspan="1">WT, PNA, VENT, INO,</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic> (L) = 31.7 &#215; (WT/70) &#215; (1 + 0.005 &#215; PNA) &#215; Finotrope &#215; INO &#215; Fventilation &#215; VENT</p><p>Finotrope = 1.09 applied if use of INO</p><p>Fventilation = 1.08 applied if use of positive pressure VENT</p><p>INO and VENT have a value of 1 if present, 0 if absent.</p></td><td align="left" colspan="1" rowspan="1">0.455 (for mean weight 1 kg, PMA 34 wks, PNA 1 day, no INO, no VENT)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sherwin et al., 2009 [<xref ref-type="bibr" rid="CR81">81</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.23 &#215; (WT/2)<sup>0.691</sup> &#215; (PMA/40)<sup>3.23</sup></td><td align="left" colspan="1" rowspan="1">0.091 (for mean weight 2 kg, PMA 30 wks)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 0.957 &#215; (WT/2)<sup>0.89</sup></td><td align="left" colspan="1" rowspan="1">0.957 (for mean weight 2 kg PMA 30 wks)</td></tr><tr><td align="left" colspan="1" rowspan="1">De Cock et al., 2012 [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left" colspan="1" rowspan="1">BW, PNA, IBU</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.0493 &#215; (BW/1.75)<sup>1.34</sup> &#215; (1+ 0.213 &#215; (PNA/2) &#215; IBU</p><p>IBU = 0.838 if co-administration of IBU</p><p><italic toggle="yes">Q</italic> (L/h) = 0.415 &#215; Cl</p></td><td align="left" colspan="1" rowspan="1">CL = 0.0493, <italic toggle="yes">Q</italic> = 0.020 (for mean BW 1.75 kg, PNA 2 days, no IBU)</td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.833 &#215; (WT/1.76)<sup>0.919</sup></p><p><italic toggle="yes">V</italic><sub>c</sub> =<italic toggle="yes">V</italic><sub>p</sub></p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 0.833</p><p><italic toggle="yes">V</italic><sub>p</sub> = 0.833</p><p>(for mean BW 1.75 kg and PNA 2 days no IBU)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Smits et al., 2015 [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left" colspan="1" rowspan="1">BW, PNA, IBU</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h) = 0.066 &#215; (BW/2.285)<sup>1.30</sup> &#215; (1+ 0.302 &#215; (PNA/2) &#215; IBU</p><p>IBU = 0.846 if co-administration of IBU</p><p><italic toggle="yes">Q</italic> (L/h) = 0.480 &#215; Cl</p></td><td align="left" colspan="1" rowspan="1">CL = 0.066, <italic toggle="yes">Q</italic> = 0.032 (for median weigh 2.1 kg BW 2.28 kg, PNA 2 days, no IBU)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 1.03 &#215; (WT/2.1)<sup>0.863</sup></p><p><italic toggle="yes">V</italic><sub>c</sub> = <italic toggle="yes">V</italic><sub>p</sub></p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 1.03</p><p><italic toggle="yes">V</italic><sub>p</sub> = 1.03</p><p>(for median weight 2.1 kg, BW 2.28 kg and PNA 2 days, no IBU)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Illamola et al., 2016 [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left" colspan="1" rowspan="1"><p>M1: WT, PNA</p><p>M2: WT, CLCr</p></td><td align="left" colspan="1" rowspan="1"><p>M1: CL (L/h) = 0.093 &#215; (WT/1.92)<sup>1.1</sup> &#215; (PNA/28)<sup>0.299</sup></p><p><italic toggle="yes">Q</italic> (L/h) = 0.051 &#215; (WT/1.92)<sup>0.995</sup></p><p>M2: CL (L/h) = 0.093 &#215; (WT/1.92)<sup>0.799</sup> &#215; (CLCr/32.28)<sup>0.659</sup></p><p><italic toggle="yes">Q</italic> (L/h) = 0.042 &#215; (WT/1.92)<sup>0.909</sup></p></td><td align="left" colspan="1" rowspan="1"><p>M1: CL = 0.093, <italic toggle="yes">Q</italic> = 0.051</p><p>M2: CL = 0.093, <italic toggle="yes">Q</italic> = 0.042 (for mean weight 1.92 kg, PNA 28 days, CLCr 32.28 ml/min)</p></td><td align="left" colspan="1" rowspan="1"><p>M1 and 2:</p><p>WT</p></td><td align="left" colspan="1" rowspan="1"><p>M1:</p><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.637 &#215; (WT/1.92)<sup>1.030</sup></p><p><italic toggle="yes">V</italic><sub>p</sub> (L) = 0.480</p><p>M2:</p><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 0.641 &#215; (WT/1.92)<sup>1.040</sup></p><p><italic toggle="yes">V</italic><sub>p</sub> (L) = 0.478</p></td><td align="left" colspan="1" rowspan="1"><p>M1:</p><p><italic toggle="yes">V</italic><sub>c</sub> = 0.637</p><p><italic toggle="yes">V</italic><sub>p</sub> = 0.48</p><p>M2:</p><p><italic toggle="yes">V</italic><sub>c</sub> = 0.641</p><p>V<sub>p</sub> = 0.48</p><p>(for mean weight 1.92 kg, PNA 28 days, CLCr 32.28 ml/min)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Amponsah et al., 2017 [<xref ref-type="bibr" rid="CR82">82</xref>]</td><td align="left" colspan="1" rowspan="1">BW</td><td align="left" colspan="1" rowspan="1">CL (L/h) = 0.153 &#215; (BW/2.5)<sup>1.31</sup></td><td align="left" colspan="1" rowspan="1">0.058</td><td align="left" colspan="1" rowspan="1">BW</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">V</italic> (L) = 2.94 &#215; (BW/2.5)<sup>1.18</sup></td><td align="left" colspan="1" rowspan="1">1.15</td></tr><tr><td align="left" colspan="1" rowspan="1">C&#225;ceres Guido et al., 2017 [<xref ref-type="bibr" rid="CR83">83</xref>]</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">0.497</td></tr><tr><td align="left" colspan="1" rowspan="1">Severino et al., 2023 [<xref ref-type="bibr" rid="CR84">84</xref>]</td><td align="left" colspan="1" rowspan="1">WT, PMA, Cr, shock, sepsis</td><td align="left" colspan="1" rowspan="1"><p>CL (L/h/70kg) = 1.79 &#215; (WT/70)<sup>0. 75</sup> &#215; (PMA/38)<sup>1.61</sup> &#215; [1 &#8722; 0.78 &#215; (Cr &#8722; 0.44)] &#215; [1 + (shock &#8722; 0) &#215; (&#8211; 0.24)] &#215; [1 + (sepsis &#8722; 0) &#215; 0.33]</p><p>Shock = 0.76 if shock present, 0 if absent</p><p>Sepsis = 1.33 if sepsis present, 0 if absent</p><p><italic toggle="yes">Q</italic> (L/h) = 0.076 &#215; WT<sup>0.75</sup></p></td><td align="left" colspan="1" rowspan="1"><p>CL = 0.057</p><p><italic toggle="yes">Q</italic> = 0.054</p></td><td align="left" colspan="1" rowspan="1">WT</td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> (L) = 25.1 &#215; (WT/70)</p><p><italic toggle="yes">V</italic><sub>p</sub> (L) = 33.5 &#215; (WT/70)</p></td><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">V</italic><sub>c</sub> = 0.359</p><p><italic toggle="yes">V</italic><sub>p</sub> = 0.439</p></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AMX, amoxicillin-clavulanic acid; AP, Apgar score at 5 minutes; BW, birth weight; CL, clearance; CLCr, creatinine clearance; CPR, creatinine production rate; Cr, creatinine (mg/dL); DA, dopamine; GA, gestational age; IBU, ibuprofen; IND, indomethacin; INO, inotropes; M, model; ND, no data; NSAID, nonsteroidal anti-inflammatory drugs; PCA, post-conceptional age; PMA, postmenstrual age; PNA, postnatal age; Q, intercompartmental clearance; <italic toggle="yes">Q</italic><sub>2</sub> and Q<sub>3</sub>, intercompartmental clearances between the central and each of the two peripheral compartments; pts, patients; RF, renal function; SGA, intrauterine growth retardation; SPI, spironolactone; TSCr, typical value of serum creatinine concentration for a specific PMA; <italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub>, volume of distribution of the central compartment; <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>, volume of distribution; VENT, artificial ventilation; <italic toggle="yes">V</italic><sub><italic toggle="yes">p</italic></sub>, volume of distribution of peripheral compartment; <italic toggle="yes">V</italic><sub><italic toggle="yes">p2</italic></sub> and <italic toggle="yes">V</italic><sub><italic toggle="yes">p3</italic></sub>, volume of distribution of peripheral compartments; <italic toggle="yes">V</italic><sub>ss</sub>, volume of distribution at steady state; wks, weeks; WT, total body weight; 1-CMT, one-compartment model; 2-CMT, two-compartment model</p><p><sup>a</sup>Values of patients from group 1: patients with vancomycin and without indomethacin</p><p><sup>b</sup>Serum creatinine (&#956;mol/L)</p><p><sup>c</sup>Weighted averages of the subgroups of included patients</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par30">This literature review identified 68 popPK models for vancomycin, gentamicin, and amikacin in neonates and infants. The most models have been developed for vancomycin (<italic toggle="yes">n</italic> = 34) because of its wide use in clinical practice and experience with TDM, followed by gentamicin (<italic toggle="yes">n</italic> = 21) and, to a lesser extent, amikacin (<italic toggle="yes">n</italic> = 13). In all three antibiotics, the most common covariate included to explain the variability in CL was WT, especially in vancomycin (83.3%). Some studies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR56">56</xref>&#8211;<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR84">84</xref>&#8211;<xref ref-type="bibr" rid="CR86">86</xref>] included this covariate in the equation using the accepted and commonly used allometric scaling of weight, with a fixed exponent of 0.75. Others [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>] reported estimated values ranging from 0.155 to 1.45. This wide range could be because the estimation of the allometric coefficient may be quite imprecise and depends mainly on the weight distribution in the subjects used to develop the popPK model [<xref ref-type="bibr" rid="CR87">87</xref>].</p><p id="Par31">Similarly, WT was the most frequent covariate used to describe the variability in <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>, especially in vancomycin (91.7%). The exponent for the allometric scale was fixed to one in most models, which is supported by fractal geometric concepts and observations from diverse areas in biology [<xref ref-type="bibr" rid="CR87">87</xref>]. However, 12 models estimated a value other than one [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. The application of allometric scaling methods for size scaling has been employed to overcome the limitations associated with simplistic weight-scaled approaches when characterizing V<sub>d</sub> and CL parameters in neonates. In general, changes in body size can affect the distribution of drugs in the body, and this can be represented by <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>. Although CL is more closely related to maturation of organ functions than size, the latter could also affect CL because of physiological development [<xref ref-type="bibr" rid="CR54">54</xref>]. Fat-free mass might be expected to estimate better than WT when there are wide variations in fat affecting body composition, although the percentage of fat is low in newborns [<xref ref-type="bibr" rid="CR87">87</xref>]. However, it is a more challenging parameter to determine in routine clinical practice than WT, although it has already been incorporated in vancomycin pediatric popPK models [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>].</p><p id="Par32">PMA seems to have a substantial influence on vancomycin (44.4%) and amikacin (36.4%) and less so on gentamicin (9.5%). Clearance pathways develop in the fetus before birth. Although PMA is the covariate most frequently used to describe age-dependent maturation in pediatric PopPK models, it is important to characterize development before birth and maturation after birth separately, so it is interesting to consider other covariates such as PNA and GA to explain the changes after birth [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. In the updated version of the Rhodin et al. [<xref ref-type="bibr" rid="CR90">90</xref>] function, PNA was included as a descriptor of renal maturation, as it describes changes after birth. The transition from the intrauterine to the extrauterine environment is linked with major changes in blood flow and oxygenation. This can cause changes in glomerular filtration rate (GFR), kidney function, and drug metabolism. Therefore, PNA maturation has been used to account for those changes in addition to that predicted using PMA [<xref ref-type="bibr" rid="CR92">92</xref>]. PMA was commonly included in popPK models using a sigmoidal function, especially in vancomycin [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. A nonlinear relationship between organ maturation and PMA has been described, which can be explained using a sigmoidal maximum response (<italic toggle="yes">E</italic><sub>max</sub>) model of gradual maturation of CL in early life leading to a mature adult CL achieved at a later age according to the Hill equation [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR90">90</xref>].</p><p id="Par33">Another covariate frequently reported to be a determinant predictor of CL in all three antibiotics was Cr, which was included in over half of the popPK models for vancomycin. Cr concentration decreases with age in the newborn; in the first few days of life, it reflects the mother&#8217;s concentrations rather than neonatal renal function, and subsequent concentrations are influenced by tubular reabsorption [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. Three studies used an equation to predict the creatinine production rate [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. Preterm infants have a slower increase in the GFR during their first weeks of life than do full-term infants [<xref ref-type="bibr" rid="CR87">87</xref>].</p><p id="Par34">Extracellular water is relatively higher in neonates than in children [<xref ref-type="bibr" rid="CR94">94</xref>]. For this reason, the <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> for hydrophilic drugs such as aminoglycosides and vancomycin is higher in neonates than in infants and older children. Extracellular water decreases during development, from 80 to 70% WT in newborns to 61.2% in 1-year-old infants [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. According to previous literature, the average <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> for aminoglycosides was 0.45 &#177; 0.1 L/kg in neonates and decreased to 0.3 &#177; 0.1 L/kg in adults. Premature neonates tend to have a larger <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> (nearer 0.5&#8211;0.55 L/kg), whereas full-term neonates tend to have smaller values (nearer 0.4&#8211;0.45 L/kg) [<xref ref-type="bibr" rid="CR95">95</xref>]. When assessing the pharmacokinetic parameters standardized for a &#8220;typical&#8221; neonate of 3 kg, the results obtained in our review for gentamicin were mean&#177; SD <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> 1.54 &#177; 0.53 L for the 1-CMT models and <italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub> 1.32 &#177; 0.08 L for the 2-CMT and 3-CMT models. For amikacin, the mean <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> was slightly higher (1.67 &#177; 0.27 L) for the 1-CMT models, and the <italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub> was 1.17 &#177; 0.19 L for the 2-CMT models. In the case of vancomycin, the mean <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> has been reported to be 0.56 &#177; 0.02 L/kg in premature neonates and ranged from 0.69 to 0.79 in infants and full-term neonates [<xref ref-type="bibr" rid="CR95">95</xref>]. In our review for the &#8220;typical&#8221; neonate, mean &#177; SD <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> was 1.75 &#177; 0.65 L for the 1-CMT models, and mean <italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub> was 1.08 &#177; 0.55 L for the 2-CMT models.</p><p id="Par35">Pathological states such as sepsis also influenced the <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> of all three antibiotics. Sepsis involves increased permeability, which is responsible for a fluid shift and may be consistent with higher <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> [<xref ref-type="bibr" rid="CR82">82</xref>]. Moreover, the volume expanders given by intravenous infusion in the sepsis state contribute to an increase in extracellular fluid volume [<xref ref-type="bibr" rid="CR73">73</xref>]. For these reasons, the <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> in neonates with sepsis [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR84">84</xref>] is higher than in neonates without sepsis. For gentamicin, Lingvall et al. showed that <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> increased by 14% in septic neonates, which implies that larger doses may be required to achieve peak therapeutic concentrations [<xref ref-type="bibr" rid="CR70">70</xref>]. Similarly, for amikacin, the septic population studied by Amponsah et al. had a higher <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> than the median (1.15 L/kg) [<xref ref-type="bibr" rid="CR82">82</xref>]. Because of the higher <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> for water-soluble drugs in neonates and the nonlinear scale of clearance, neonates must receive higher doses of gentamicin per kilogram of bodyweight than older pediatric patients and adults to achieve comparable plasma and tissue concentrations [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>].</p><p id="Par36">The aminoglycosides are mainly eliminated by glomerular filtration, and their elimination rates are reduced at birth. In preterm newborns, the GFR corresponds to 25&#8211;30% of the adult value [<xref ref-type="bibr" rid="CR16">16</xref>]. CL of aminoglycosides is lower in neonates than in more mature infants [<xref ref-type="bibr" rid="CR98">98</xref>]. The mean &#177; SD CL in neonates has been reported to be 0.05 &#177; 0.01 L/kg/h, increasing to 0.13 &#177; 0.03 L/h/kg in children and 0.08 &#177; 0.03 L/kg/h in adults [<xref ref-type="bibr" rid="CR95">95</xref>]. The mean &#177; SD values obtained for gentamicin in our review for the &#8220;typical&#8221; neonate were CL 0.27 &#177; 0.49 L/h for 1-CMT models and 1.32 &#177; 0.08 L/h for the 2-CMT and 3-CMT models. For amikacin, the mean &#177; SD CL was 0.19 &#177; 0.07 L/h for 1-CMT models and 0.24 &#177; 0.13 L/h for 2-CMT models. In newborns, renal function increases rapidly; GFR tends to double during the first 14 days of life because of the rapid changes in glomerular hemodynamics, which are characterized by an increase in arterial blood pressure and renal blood flow and a decrease in renal vascular resistance [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. CL of aminoglycosides is lower in low-birth-weight neonates than in non-premature and normal weight newborns [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>].</p><p id="Par37">Similarly, vancomycin CL increases with PMA and PNA, leading to a greater elimination rate constant and shorter half-life in premature neonates [<xref ref-type="bibr" rid="CR100">100</xref>]. In the review by Chung et al. [<xref ref-type="bibr" rid="CR5">5</xref>], the typical CL for neonates ranged from 0.014 to 0.273 L/kg/h (median 0.06 L/kg/h). In our review, the median for a &#8220;typical&#8221; neonate was 0.18 L/h (0.05&#8211;4.33 L/h) in the 1-CMT models and 0.20 L/h (0.081&#8211;0.45 L/h) in the 2-CMT models.</p><p id="Par38">The data of the pharmacodynamic targets included in our review show how these targets have evolved over time, especially for vancomycin. Historically, vancomycin dosing has been titrated to obtain serum trough concentrations of 10&#8211;15 mg/L for mild infections and 15&#8211;20 mg/L for severe infections [<xref ref-type="bibr" rid="CR6">6</xref>]. However, several vancomycin pharmacodynamic targets are currently available for neonates. In the initial studies, peak and trough were the most used parameters for monitoring. However, there has been a transition from trough concentrations to area under the concentration&#8211;time curve over minimum inhibitory concentrations (AUC<sub>0&#8722;24</sub>/MIC) with a target of 400&#8211;600 [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR57">57</xref>&#8211;<xref ref-type="bibr" rid="CR59">59</xref>]. Peaks and troughs are still used for gentamicin. In most studies, the target was trough ~1&#8211;2 mg/L and peak ~ 5&#8211;10 mg/L, although some studies used higher peaks [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. The variation in trough values was greater for amikacin, with target values ~1&#8211;3 mg/L. However, for the peak, there appears to be consensus of ~25&#8211;35 mg/L. Data for the pharmacodynamic targets of each study are summarized in Table <xref rid="MOESM1" ref-type="media">S1</xref> in the supplementary material.</p><p id="Par39">The limited antibiotic blood samples in most studies meant that a 1-CMT approach was more frequently described than a 2-CMT approach. Nevertheless, in all three antibiotics, the studies with more samples used 2-CMT or 3-CMT models to describe the pharmacokinetic parameters (CL and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>). Aminoglycosides exhibit a three-compartment distribution when given intravenously, but the <italic toggle="yes">V</italic><sub><italic toggle="yes">c</italic></sub> is quite small, at approximately one-third to one-half of the volumes used for general dosing with 1-CMT approaches [<xref ref-type="bibr" rid="CR101">101</xref>]. The first distribution phase, during the first hour, is generally not detected because it is masked by the infusion time (0.5&#8211;1 h) [<xref ref-type="bibr" rid="CR95">95</xref>]. For vancomycin, 1-CMT, 2-CMT, and 3-CMT approaches have all been described in adults, although 1-CMT models seem to be a valid tool for predicting serum concentrations in the post-distribution phase in newborns [<xref ref-type="bibr" rid="CR102">102</xref>].</p><p id="Par40">Optimal dosing of these three antibiotics is challenging in newborns and infants because of their physiological characteristics and the pharmacokinetic characteristics of the drugs. The higher level of extracellular fluids per kilogram in neonates affect the <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> of water-soluble medications. Moreover, as nephrogenesis is completed late in gestation, the renal function of premature neonates is compromised regarding renally excreted drugs [<xref ref-type="bibr" rid="CR97">97</xref>]. Vancomycin and aminoglycosides have narrow therapeutic margins and can easily lead to nephrotoxicity. Therefore, TDM has a fundamental role in this population, not only to avoid toxicity but also to attain the desired pharmacokinetic/pharmacodynamic target [<xref ref-type="bibr" rid="CR7">7</xref>]. PopPK models combined with TDM help to achieve the goal of MIPD, improving drug treatment outcomes by achieving an optimal balance between beneficial effects and toxicity [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par41">TDM using Bayesian forecasting can be a valuable tool for optimizing drug therapy in clinical practice [<xref ref-type="bibr" rid="CR5">5</xref>]. A Bayesian approach allows the estimation of individual pharmacokinetic parameters (i.e. CL and <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub>) based on the data but also considers prior information from the literature. Nevertheless, before implementing a popPK model into clinical practice, an external validation should be conducted to evaluate its predictive performance. In addition, other aspects that need to be considered when selecting one pharmacokinetic model over another are the characteristics of the population in which it has been developed and the covariates, as well as the complexity and feasibility of adapting the model to a certain software.</p><p id="Par42">This research highlights the numerous attempts that have been made to characterize the pharmacokinetics of antibiotics in newborns and infants to respond to the special characteristics of this population. The multiple model properties (constants and functions) and covariates included in the popPK models account for the differences among this population regarding age, physiological development, and comorbidities. From our review, for each of the antibiotics, different models could be considered to assess their performance in clinical practice before implementing them. For vancomycin and gentamycin, a meta-analysis was carried out for each to determine a &#8220;meta-model&#8221; for neonates [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. For vancomycin, a 2-CMT &#8220;meta-model&#8221; was built using NONMEM<sup>&#174;</sup> incorporating the current weight (CW), PMA, and Cr as significant covariates for CL [<xref ref-type="bibr" rid="CR103">103</xref>]. For gentamycin, a 3-CMT &#8220;meta-model&#8221; was built using NONMEM<sup>&#174;</sup> with the covariates WT, PMA, PNA, and Cr for the CL and WT for the <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par43">Our review provides a comprehensive summary of all the evidence published to date related to popPK models for vancomycin, gentamicin, and amikacin in neonates. Previous reviews focused on pediatrics (children, infants, and neonates) and included patients with and without pathologies as well as those undergoing extracorporeal membrane oxygenation and/or controlled hypothermia [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. However, our review focuses only on neonates and infants because of the physiological particularities of this population and includes only individuals with no previous pathologies, as we believe that a different approach is required for pathologic conditions. We included observational studies and clinical trials conducted in different countries to integrate a large number of popPK models developed from newborns with different racial backgrounds. Nevertheless, several limitations must be acknowledged when interpreting the results. First, our review cannot be classified as a systematic review since the literature search, data extraction, and interpretation of the results was conducted by a single investigator. However, any discrepancies were resolved with input from a second investigator. No formal evaluation of the quality of the included studies was performed. Second, the biggest limitation of the included studies was that most of the popPK models lacked external validation, which is essential to evaluate whether the models extend to neonates outside the original population used to develop the model and to assess bias and precision [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The US Food and Drug Administration considers external validation to be the most stringent method for testing a developed model [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. Third, the number of blood samples used to develop some models was limited. This explains why the 1-CMT approach was more commonly described than the 2-CMT or 3-CMT approach. Fourth, our review focuses only on the neonatal and infant population because of its unique characteristics, especially in terms of body water content and lower fat content per kilogram, which influences the V<sub>d</sub> of hydrophilic and lipophilic drugs and therefore drug distribution. Drug metabolism and clearance in neonates is influenced by size-related changes, ontogeny of isoenzymes, and maturation of renal function. Therefore, it is especially important to include a maturation function (on top of allometric scaling) in the equations for describing those changes. Although the pediatric population shares some physiological characteristics with the neonatal population, only models that included neonates in their development may be suitable to use in this population. Fifth, it is possible that some published popPK models may have been missed in the search and are not included in the review.</p><p id="Par44">Considering these limitations, further research should prioritize the external validation of the popPK models developed, as advocated by the US Food and Drug Administration. External validation was performed in &lt;10% of published pharmacokinetic models, and questions concerning the clinical applicability of models frequently remain unaddressed [<xref ref-type="bibr" rid="CR15">15</xref>]. Moreover, endeavors should be directed toward expanding the scope of prospective studies with optimal sampling designs. By addressing these issues, future research can substantially contribute to advancing the reliability, applicability, and clinical relevance of popPK models for neonates.</p></sec><sec id="Sec16"><title>Conclusions</title><p id="Par45">Overall, this study includes the best available evidence of neonatal popPK models used for some of the most commonly prescribed antibiotics (vancomycin, gentamicin, and amikacin) and enhances our understanding of them. WT, PMA, and Cr, followed by PNA, were the most frequent covariates included in CL equations, and WT was most commonly included in <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> equations. 1-CMT approaches were more commonly described than 2-CMT approaches, probably because of the difficulties of obtaining blood samples in neonates. The substantial variability between the popPK models for all three antibiotics and the characteristics of study populations, coupled with the limited prospective studies and the absence of external validation of most models, makes it impossible to implement a single, globally applicable, and uniform popPK model for all neonates.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2024_1459_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 138 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2024_1459_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file2 (DOCX 142 KB)</p></caption></media></supplementary-material></p></sec></body><back><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par46">The authors report no conflicts of interest.</p></notes><notes id="FPar2"><title>Ethical Approval</title><p id="Par47">Not applicable.</p></notes><notes id="FPar3"><title>Consent to Participate</title><p id="Par48">Not applicable.</p></notes><notes id="FPar4"><title>Consent for Publication</title><p id="Par49">Not applicable.</p></notes><notes id="FPar5"><title>Availability of Data and Materials</title><p id="Par50">Not applicable.</p></notes><notes id="FPar6"><title>Code Availability</title><p id="Par51">Not applicable</p></notes><notes id="FPar7" notes-type="author-contribution"><title>Author Contributions</title><p id="Par52">MAF contributed to the conception and design of the study, data search, extraction, and interpretation and to the drafting of the manuscript. CB contributed to the conception and design of the study, methodology assessment, data interpretation, supervision, and revision of the manuscript. MRR and DSM contributed amendments to the manuscript and revised it critically.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>P</given-names></name><name name-style="western"><surname>Qazi</surname><given-names>S</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>R</given-names></name><name name-style="western"><surname>Velaphi</surname><given-names>S</given-names></name><name name-style="western"><surname>Bielicki</surname><given-names>J</given-names></name><name name-style="western"><surname>Nambiar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Antibiotics needed to treat multidrug-resistant infections in neonates</article-title><source>Bull World Health Organ</source><year>2022</year><volume>100</volume><issue>12</issue><fpage>797</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.2471/BLT.22.288623</pub-id><pub-id pub-id-type="pmid">36466207</pub-id><pub-id pub-id-type="pmcid">PMC9706347</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Williams P, Qazi S, Agarwal R, Velaphi S, Bielicki J, Nambiar S, et al. Antibiotics needed to treat multidrug-resistant infections in neonates. Bull World Health Organ. 2022;100(12):797&#8211;807.<pub-id pub-id-type="pmid">36466207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2471/BLT.22.288623</pub-id><pub-id pub-id-type="pmcid">PMC9706347</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleischmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Reichert</surname><given-names>F</given-names></name><name name-style="western"><surname>Cassini</surname><given-names>A</given-names></name><name name-style="western"><surname>Horner</surname><given-names>R</given-names></name><name name-style="western"><surname>Harder</surname><given-names>T</given-names></name><name name-style="western"><surname>Markwart</surname><given-names>R</given-names></name><etal/></person-group><article-title>Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis</article-title><source>Arch Dis Child</source><year>2021</year><volume>106</volume><issue>8</issue><fpage>745</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2020-320217</pub-id><pub-id pub-id-type="pmid">33483376</pub-id><pub-id pub-id-type="pmcid">PMC8311109</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Child. 2021;106(8):745&#8211;52.<pub-id pub-id-type="pmid">33483376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/archdischild-2020-320217</pub-id><pub-id pub-id-type="pmcid">PMC8311109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivanandan</surname><given-names>S</given-names></name><name name-style="western"><surname>Jain</surname><given-names>K</given-names></name><name name-style="western"><surname>Plakkal</surname><given-names>N</given-names></name><name name-style="western"><surname>Bahl</surname><given-names>M</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>T</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name><etal/></person-group><article-title>Issues, challenges, and the way forward in conducting clinical trials among neonates: investigators&#8217; perspective</article-title><source>J Perinatol</source><year>2019</year><volume>39</volume><issue>S1</issue><fpage>20</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/s41372-019-0469-8</pub-id><pub-id pub-id-type="pmid">31485015</pub-id><pub-id pub-id-type="pmcid">PMC8075906</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Sivanandan S, Jain K, Plakkal N, Bahl M, Sahoo T, Mukherjee S, et al. Issues, challenges, and the way forward in conducting clinical trials among neonates: investigators&#8217; perspective. J Perinatol. 2019;39(S1):20&#8211;30.<pub-id pub-id-type="pmid">31485015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41372-019-0469-8</pub-id><pub-id pub-id-type="pmcid">PMC8075906</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marsot</surname><given-names>A</given-names></name><name name-style="western"><surname>Boulamery</surname><given-names>A</given-names></name><name name-style="western"><surname>Bruguerolle</surname><given-names>B</given-names></name><name name-style="western"><surname>Simon</surname><given-names>N</given-names></name></person-group><article-title>Population pharmacokinetic analysis during the first 2 years of life: an overview</article-title><source>Clin Pharmacokinet</source><year>2012</year><volume>51</volume><issue>12</issue><fpage>787</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1007/s40262-012-0015-8</pub-id><pub-id pub-id-type="pmid">23179579</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Marsot A, Boulamery A, Bruguerolle B, Simon N. Population pharmacokinetic analysis during the first 2 years of life: an overview. Clin Pharmacokinet. 2012;51(12):787&#8211;98.<pub-id pub-id-type="pmid">23179579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-012-0015-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>E</given-names></name><name name-style="western"><surname>Sen</surname><given-names>J</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P</given-names></name><name name-style="western"><surname>Seto</surname><given-names>W</given-names></name></person-group><article-title>Population pharmacokinetic models of vancomycin in paediatric patients: a systematic review</article-title><source>Clin Pharmacokinet</source><year>2021</year><volume>60</volume><issue>8</issue><fpage>985</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1007/s40262-021-01027-9</pub-id><pub-id pub-id-type="pmid">34002357</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Chung E, Sen J, Patel P, Seto W. Population pharmacokinetic models of vancomycin in paediatric patients: a systematic review. Clin Pharmacokinet. 2021;60(8):985&#8211;1001.<pub-id pub-id-type="pmid">34002357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-021-01027-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SM</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>MJ</given-names></name></person-group><article-title>Population pharmacokinetics and dose optimization of vancomycin in neonates</article-title><source>Sci Rep</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41598-021-85529-3</pub-id><pub-id pub-id-type="pmid">33731764</pub-id><pub-id pub-id-type="pmcid">PMC7969932</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lee SM, Yang S, Kang S, Chang MJ. Population pharmacokinetics and dose optimization of vancomycin in neonates. Sci Rep. 2021. 10.1038/s41598-021-85529-3.<pub-id pub-id-type="pmid">33731764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-85529-3</pub-id><pub-id pub-id-type="pmcid">PMC7969932</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marta</surname><given-names>MT</given-names></name><name name-style="western"><surname>Marta</surname><given-names>AM</given-names></name><name name-style="western"><surname>Laura</surname><given-names>HH</given-names></name><name name-style="western"><surname>Victoria</surname><given-names>GNM</given-names></name></person-group><article-title>Target attainment and clinical efficacy for vancomycin in neonates: systematic review</article-title><source>Antibiotics (Basel).</source><year>2021</year><volume>10</volume><issue>4</issue><fpage>347</fpage><pub-id pub-id-type="doi">10.3390/antibiotics10040347</pub-id><pub-id pub-id-type="pmid">33805874</pub-id><pub-id pub-id-type="pmcid">PMC8064372</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Marta MT, Marta AM, Laura HH, Victoria GNM. Target attainment and clinical efficacy for vancomycin in neonates: systematic review. Antibiotics (Basel). 2021;10(4):347.<pub-id pub-id-type="pmid">33805874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics10040347</pub-id><pub-id pub-id-type="pmcid">PMC8064372</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kearns</surname><given-names>GL</given-names></name><name name-style="western"><surname>Abdel-Rahman</surname><given-names>SM</given-names></name><name name-style="western"><surname>Alander</surname><given-names>SW</given-names></name><name name-style="western"><surname>Blowey</surname><given-names>DL</given-names></name><name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>RE</given-names></name></person-group><article-title>Developmental pharmacology&#8212;drug disposition, action, and therapy in infants and children</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><issue>12</issue><fpage>1157</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1056/NEJMra035092</pub-id><pub-id pub-id-type="pmid">13679531</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology&#8212;drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157&#8211;67.<pub-id pub-id-type="pmid">13679531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra035092</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Puig M. Body composition and growth. In: Walker WA, Watkins JB, editors. Nutrition in Pediatrics, 2nd edn. Hamilton, Ontario, BC Decker; 1996.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Mian</surname><given-names>P</given-names></name><name name-style="western"><surname>van den Anker</surname><given-names>JN</given-names></name></person-group><article-title>Developmental pharmacokinetics in neonates: maturational changes and beyond</article-title><source>Curr Pharm Des</source><year>2018</year><volume>23</volume><issue>38</issue><fpage>5769</fpage><lpage>5778</lpage><pub-id pub-id-type="doi">10.2174/1381612823666170926121124</pub-id><pub-id pub-id-type="pmid">28950819</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Allegaert K, Mian P, van den Anker JN. Developmental pharmacokinetics in neonates: maturational changes and beyond. Curr Pharm Des. 2018;23(38):5769&#8211;78.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612823666170926121124</pub-id><pub-id pub-id-type="pmid">28950819</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ette</surname><given-names>EI</given-names></name><name name-style="western"><surname>Williams</surname><given-names>PJ</given-names></name></person-group><article-title>Population pharmacokinetics I: background, concepts, and models</article-title><source>Ann Pharmacother</source><year>2004</year><volume>38</volume><issue>10</issue><fpage>1702</fpage><lpage>1706</lpage><pub-id pub-id-type="doi">10.1345/aph.1D374</pub-id><pub-id pub-id-type="pmid">15328391</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004;38(10):1702&#8211;6.<pub-id pub-id-type="pmid">15328391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1345/aph.1D374</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bigos</surname><given-names>KL</given-names></name><name name-style="western"><surname>Bies</surname><given-names>RR</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>BG</given-names></name></person-group><article-title>Population pharmacokinetics in geriatric psychiatry</article-title><source>Am J Geriatr Psychiatry</source><year>2006</year><volume>14</volume><issue>12</issue><fpage>993</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1097/01.JGP.0000224330.73063.6c</pub-id><pub-id pub-id-type="pmid">17138806</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bigos KL, Bies RR, Pollock BG. Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry. 2006;14(12):993&#8211;1003.<pub-id pub-id-type="pmid">17138806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.JGP.0000224330.73063.6c</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Poweleit</surname><given-names>EA</given-names></name><name name-style="western"><surname>Paice</surname><given-names>K</given-names></name><name name-style="western"><surname>Somers</surname><given-names>KM</given-names></name><name name-style="western"><surname>Pavia</surname><given-names>K</given-names></name><name name-style="western"><surname>Vinks</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2023</year><volume>12</volume><issue>12</issue><fpage>1827</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1002/psp4.13056</pub-id><pub-id pub-id-type="pmid">37771190</pub-id><pub-id pub-id-type="pmcid">PMC10725261</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Taylor ZL, Poweleit EA, Paice K, Somers KM, Pavia K, Vinks AA, et al. Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing. CPT Pharmacometrics Syst Pharmacol. 2023;12(12):1827&#8211;45.<pub-id pub-id-type="pmid">37771190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.13056</pub-id><pub-id pub-id-type="pmcid">PMC10725261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>YX</given-names></name><name name-style="western"><surname>Wen</surname><given-names>H</given-names></name><name name-style="western"><surname>Niu</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Z</given-names></name></person-group><article-title>External evaluation of vancomycin population pharmacokinetic models at two clinical centers</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>623907</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.623907</pub-id><pub-id pub-id-type="pmid">33897418</pub-id><pub-id pub-id-type="pmcid">PMC8058705</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Liu YX, Wen H, Niu WJ, Li JJ, Li ZL, Jiao Z. External evaluation of vancomycin population pharmacokinetic models at two clinical centers. Front Pharmacol. 2021;12: 623907.<pub-id pub-id-type="pmid">33897418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.623907</pub-id><pub-id pub-id-type="pmcid">PMC8058705</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stockmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Hersh</surname><given-names>AL</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JK</given-names></name><name name-style="western"><surname>Bhongsatiern</surname><given-names>J</given-names></name><name name-style="western"><surname>Korgenski</surname><given-names>EK</given-names></name><name name-style="western"><surname>Spigarelli</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Predictive performance of a vancomycin population pharmacokinetic model in neonates</article-title><source>Infect Dis Ther</source><year>2015</year><volume>4</volume><issue>2</issue><fpage>187</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1007/s40121-015-0067-9</pub-id><pub-id pub-id-type="pmid">25998107</pub-id><pub-id pub-id-type="pmcid">PMC4471056</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski EK, Spigarelli MG, et al. Predictive performance of a vancomycin population pharmacokinetic model in neonates. Infect Dis Ther. 2015;4(2):187&#8211;98.<pub-id pub-id-type="pmid">25998107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40121-015-0067-9</pub-id><pub-id pub-id-type="pmcid">PMC4471056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crcek</surname><given-names>M</given-names></name><name name-style="western"><surname>Zdovc</surname><given-names>J</given-names></name><name name-style="western"><surname>Kerec</surname><given-names>KM</given-names></name></person-group><article-title>A review of population pharmacokinetic models of gentamicin in paediatric patients</article-title><source>J Clin Pharm Ther</source><year>2019</year><volume>44</volume><issue>5</issue><fpage>659</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1111/jcpt.12850</pub-id><pub-id pub-id-type="pmid">31102287</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Crcek M, Zdovc J, Kerec KM. A review of population pharmacokinetic models of gentamicin in paediatric patients. J Clin Pharm Ther. 2019;44(5):659&#8211;74.<pub-id pub-id-type="pmid">31102287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcpt.12850</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Illamola</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sherwin</surname><given-names>CM</given-names></name><name name-style="western"><surname>van Hasselt</surname><given-names>JGC</given-names></name></person-group><article-title>Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses</article-title><source>Clin Pharmacokinet</source><year>2018</year><volume>57</volume><issue>10</issue><fpage>1217</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1007/s40262-018-0641-x</pub-id><pub-id pub-id-type="pmid">29572662</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Illamola SM, Sherwin CM, van Hasselt JGC. Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses. Clin Pharmacokinet. 2018;57(10):1217&#8211;28.<pub-id pub-id-type="pmid">29572662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-018-0641-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engle</surname><given-names>W</given-names></name></person-group><article-title>Age terminology during the perinatal period</article-title><source>Pediatrics</source><year>2004</year><volume>114</volume><issue>5</issue><fpage>1362</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1542/peds.2004-1915</pub-id><pub-id pub-id-type="pmid">15520122</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Engle W. Age terminology during the perinatal period. Pediatrics. 2004;114(5):1362&#8211;4.<pub-id pub-id-type="pmid">15520122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2004-1915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cristea</surname><given-names>S</given-names></name><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Falcao</surname><given-names>AC</given-names></name><name name-style="western"><surname>Falcao</surname><given-names>F</given-names></name><name name-style="western"><surname>Silva</surname><given-names>R</given-names></name><name name-style="western"><surname>Smits</surname><given-names>A</given-names></name><etal/></person-group><article-title>Larger dose reductions of vancomycin required in neonates with patent ductus arteriosus receiving indomethacin versus ibuprofen</article-title><source>Antimicrob Agents Chemother</source><year>2019</year><volume>63</volume><issue>8</issue><fpage>e00853</fpage><lpage>e919</lpage><pub-id pub-id-type="doi">10.1128/AAC.00853-19</pub-id><pub-id pub-id-type="pmid">31182538</pub-id><pub-id pub-id-type="pmcid">PMC6658745</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Cristea S, Allegaert K, Falcao AC, Falcao F, Silva R, Smits A, et al. Larger dose reductions of vancomycin required in neonates with patent ductus arteriosus receiving indomethacin versus ibuprofen. Antimicrob Agents Chemother. 2019;63(8):e00853-e919.<pub-id pub-id-type="pmid">31182538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00853-19</pub-id><pub-id pub-id-type="pmcid">PMC6658745</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarugula</surname><given-names>P</given-names></name><name name-style="western"><surname>Akcan-Arikan</surname><given-names>A</given-names></name><name name-style="western"><surname>Munoz-Rivas</surname><given-names>F</given-names></name><name name-style="western"><surname>Moffett</surname><given-names>BS</given-names></name><name name-style="western"><surname>Ivaturi</surname><given-names>V</given-names></name><name name-style="western"><surname>Rios</surname><given-names>D</given-names></name></person-group><article-title>Optimizing vancomycin dosing and monitoring in neonates and infants using population pharmacokinetic modeling</article-title><source>Antimicrob Agents Chemother</source><year>2022</year><pub-id pub-id-type="doi">10.1128/aac.01899-21</pub-id><pub-id pub-id-type="pmid">35293782</pub-id><pub-id pub-id-type="pmcid">PMC9046768</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Jarugula P, Akcan-Arikan A, Munoz-Rivas F, Moffett BS, Ivaturi V, Rios D. Optimizing vancomycin dosing and monitoring in neonates and infants using population pharmacokinetic modeling. Antimicrob Agents Chemother. 2022. 10.1128/aac.01899-21.<pub-id pub-id-type="pmid">35293782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.01899-21</pub-id><pub-id pub-id-type="pmcid">PMC9046768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seay</surname><given-names>RE</given-names></name><name name-style="western"><surname>Brundage</surname><given-names>RC</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>PD</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>CG</given-names></name><name name-style="western"><surname>Edgren</surname><given-names>BE</given-names></name></person-group><article-title>Population pharmacokinetics of vancomycin in neonates</article-title><source>Clin Pharmacol Ther</source><year>1994</year><volume>56</volume><issue>2</issue><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/clpt.1994.120</pub-id><pub-id pub-id-type="pmid">8062493</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther. 1994;56(2):169&#8211;75.<pub-id pub-id-type="pmid">8062493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1994.120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burstein</surname><given-names>AH</given-names></name><name name-style="western"><surname>Gal</surname><given-names>P</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Bcps</surname><given-names>P</given-names></name><name name-style="western"><surname>Pharmd</surname><given-names>AF</given-names></name></person-group><article-title>Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory</article-title><source>Ann Pharmacother</source><year>1997</year><volume>31</volume><issue>9</issue><fpage>980</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1177/106002809703100904</pub-id><pub-id pub-id-type="pmid">9296235</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Burstein AH, Gal P, Forrest A, Bcps P, Pharmd AF. Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory. Ann Pharmacother. 1997;31(9):980&#8211;3.<pub-id pub-id-type="pmid">9296235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/106002809703100904</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capparelli</surname><given-names>EV</given-names></name><name name-style="western"><surname>Lane</surname><given-names>FR</given-names></name><name name-style="western"><surname>Romanowski</surname><given-names>GL</given-names></name><name name-style="western"><surname>McFeely</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Murray</surname><given-names>W</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>P</given-names></name><etal/></person-group><article-title>The influences of renal function and maturation on vancomycin elimination in newborns and infants</article-title><source>Clin Pharmacol</source><year>2001</year><volume>41</volume><issue>9</issue><fpage>927</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1177/009127000104100901</pub-id><pub-id pub-id-type="pmid">11549096</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Capparelli EV, Lane FR, Romanowski GL, McFeely EJ, Murray W, Sousa P, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. Clin Pharmacol. 2001;41(9):927&#8211;34.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00912700122010898</pub-id><pub-id pub-id-type="pmid">11549096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuchs</surname><given-names>A</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>M</given-names></name><name name-style="western"><surname>Giannoni</surname><given-names>E</given-names></name><name name-style="western"><surname>Werner</surname><given-names>D</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T</given-names></name><name name-style="western"><surname>Widmer</surname><given-names>N</given-names></name><etal/></person-group><article-title>Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates</article-title><source>Br J Clin Pharmacol</source><year>2014</year><volume>78</volume><issue>5</issue><fpage>1090</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1111/bcp.12444</pub-id><pub-id pub-id-type="pmid">24938850</pub-id><pub-id pub-id-type="pmcid">PMC4243884</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Fuchs A, Guidi M, Giannoni E, Werner D, Buclin T, Widmer N, et al. Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. Br J Clin Pharmacol. 2014;78(5):1090&#8211;101.<pub-id pub-id-type="pmid">24938850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.12444</pub-id><pub-id pub-id-type="pmcid">PMC4243884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelman</surname><given-names>A</given-names></name></person-group><article-title>Estimation of gentamicin clearance and volume of distribution in neonates and young children</article-title><source>Br J Clin Pharmacol</source><year>1984</year><volume>18</volume><issue>5</issue><fpage>685</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1984.tb02530.x</pub-id><pub-id pub-id-type="pmid">6508978</pub-id><pub-id pub-id-type="pmcid">PMC1463552</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kelman A. Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br J Clin Pharmacol. 1984;18(5):685&#8211;92.<pub-id pub-id-type="pmid">6508978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1984.tb02530.x</pub-id><pub-id pub-id-type="pmcid">PMC1463552</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomson</surname><given-names>A</given-names></name><name name-style="western"><surname>Wayb</surname><given-names>S</given-names></name><name name-style="western"><surname>Bryson</surname><given-names>S</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>E</given-names></name><name name-style="western"><surname>Kelman</surname><given-names>A</given-names></name><name name-style="western"><surname>Whitinga</surname><given-names>B</given-names></name></person-group><article-title>Population pharmacokinetics of gentamicin in neonates</article-title><source>Dev Pharmacol Ther</source><year>1988</year><volume>11</volume><issue>3</issue><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1159/000457685</pub-id><pub-id pub-id-type="pmid">3289859</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Thomson A, Wayb S, Bryson S, McGovern E, Kelman A, Whitinga B. Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther. 1988;11(3):173&#8211;9.<pub-id pub-id-type="pmid">3289859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000457685</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izquierdo</surname><given-names>M</given-names></name><name name-style="western"><surname>Lanao</surname><given-names>JM</given-names></name><name name-style="western"><surname>Cervero</surname><given-names>L</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>NV</given-names></name><name name-style="western"><surname>Dom&#237;nguez-Gil</surname><given-names>A</given-names></name></person-group><article-title>Population pharmacokinetics of gentamicin in premature infants</article-title><source>Ther Drug Monit</source><year>1992</year><volume>14</volume><issue>3</issue><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1097/00007691-199206000-00001</pub-id><pub-id pub-id-type="pmid">1412601</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Izquierdo M, Lanao JM, Cervero L, Jimenez NV, Dom&#237;nguez-Gil A. Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit. 1992;14(3):177&#8211;83.<pub-id pub-id-type="pmid">1412601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-199206000-00001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Touw</surname><given-names>D</given-names></name><name name-style="western"><surname>Proost</surname><given-names>J</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>R</given-names></name><name name-style="western"><surname>Lafeber</surname><given-names>H</given-names></name><name name-style="western"><surname>van Weissenbruch</surname><given-names>M</given-names></name></person-group><article-title>Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus</article-title><source>Pharm World Sci</source><year>2001</year><volume>23</volume><issue>5</issue><fpage>200</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1023/A:1012490704731</pub-id><pub-id pub-id-type="pmid">11721679</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Touw D, Proost J, Stevens R, Lafeber H, van Weissenbruch M. Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus. Pharm World Sci. 2001;23(5):200&#8211;4.<pub-id pub-id-type="pmid">11721679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1012490704731</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Cock</surname><given-names>RFW</given-names></name><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Schreuder</surname><given-names>MF</given-names></name><name name-style="western"><surname>Sherwin</surname><given-names>CMT</given-names></name><name name-style="western"><surname>De Hoog</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Den Anker</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance</article-title><source>Clin Pharmacokinet</source><year>2012</year><volume>51</volume><issue>2</issue><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.2165/11595640-000000000-00000</pub-id><pub-id pub-id-type="pmid">22229883</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">De Cock RFW, Allegaert K, Schreuder MF, Sherwin CMT, De Hoog M, Van Den Anker JN, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51(2):105&#8211;17.<pub-id pub-id-type="pmid">22229883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11595640-000000000-00000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Illamola</surname><given-names>SM</given-names></name><name name-style="western"><surname>Colom</surname><given-names>H</given-names></name><name name-style="western"><surname>van Hasselt</surname><given-names>JGC</given-names></name></person-group><article-title>Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies</article-title><source>Br J Clin Pharmacol</source><year>2016</year><volume>82</volume><issue>3</issue><fpage>793</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1111/bcp.13016</pub-id><pub-id pub-id-type="pmid">27198625</pub-id><pub-id pub-id-type="pmcid">PMC5338126</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Illamola SM, Colom H, van Hasselt JGC. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Br J Clin Pharmacol. 2016;82(3):793&#8211;805.<pub-id pub-id-type="pmid">27198625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.13016</pub-id><pub-id pub-id-type="pmcid">PMC5338126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matcha</surname><given-names>S</given-names></name><name name-style="western"><surname>Dillibatcha</surname><given-names>J</given-names></name><name name-style="western"><surname>Raju</surname><given-names>AP</given-names></name><name name-style="western"><surname>Chaudhari</surname><given-names>BB</given-names></name><name name-style="western"><surname>Moorkoth</surname><given-names>S</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Predictive performance of population pharmacokinetic models for amikacin in term neonates</article-title><source>Pediatr Drugs</source><year>2023</year><volume>25</volume><issue>3</issue><fpage>365</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1007/s40272-023-00564-z</pub-id><pub-id pub-id-type="pmcid">PMC10097735</pub-id><pub-id pub-id-type="pmid">36943583</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Matcha S, Dillibatcha J, Raju AP, Chaudhari BB, Moorkoth S, Lewis LE, et al. Predictive performance of population pharmacokinetic models for amikacin in term neonates. Pediatr Drugs. 2023;25(3):365&#8211;75.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40272-023-00564-z</pub-id><pub-id pub-id-type="pmcid">PMC10097735</pub-id><pub-id pub-id-type="pmid">36943583</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smits</surname><given-names>A</given-names></name><name name-style="western"><surname>De Cock</surname><given-names>RFW</given-names></name><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Vanhaesebrouck</surname><given-names>S</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>Knibbe</surname><given-names>CAJ</given-names></name></person-group><article-title>Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice</article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><issue>10</issue><fpage>6344</fpage><lpage>6351</lpage><pub-id pub-id-type="doi">10.1128/AAC.01157-15</pub-id><pub-id pub-id-type="pmid">26248375</pub-id><pub-id pub-id-type="pmcid">PMC4576045</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Smits A, De Cock RFW, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CAJ. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59(10):6344&#8211;51.<pub-id pub-id-type="pmid">26248375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01157-15</pub-id><pub-id pub-id-type="pmcid">PMC4576045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaible</surname><given-names>DH</given-names></name><name name-style="western"><surname>Rocci</surname><given-names>ML</given-names></name><name name-style="western"><surname>Alpert</surname><given-names>GA</given-names></name><name name-style="western"><surname>Campos</surname><given-names>JM</given-names></name><name name-style="western"><surname>Paul</surname><given-names>MH</given-names></name><name name-style="western"><surname>Polin</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Vancomycin pharmacokinetics in infants</article-title><source>Pediatr Infect Dis J</source><year>1986</year><volume>5</volume><issue>3</issue><fpage>304</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1097/00006454-198605000-00006</pub-id><pub-id pub-id-type="pmid">3725640</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Schaible DH, Rocci ML, Alpert GA, Campos JM, Paul MH, Polin RA, et al. Vancomycin pharmacokinetics in infants. Pediatr Infect Dis J. 1986;5(3):304&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00006454-198605000-00006</pub-id><pub-id pub-id-type="pmid">3725640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asbury</surname><given-names>WH</given-names></name><name name-style="western"><surname>Darsey</surname><given-names>EH</given-names></name><name name-style="western"><surname>Rose</surname><given-names>WB</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>JE</given-names></name><name name-style="western"><surname>Buffington</surname><given-names>DE</given-names></name><name name-style="western"><surname>Capers</surname><given-names>CC</given-names></name></person-group><article-title>Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation</article-title><source>Ann Pharmacother</source><year>1993</year><volume>27</volume><issue>4</issue><fpage>490</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1177/106002809302700417</pub-id><pub-id pub-id-type="pmid">8477127</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother. 1993;27(4):490&#8211;6.<pub-id pub-id-type="pmid">8477127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/106002809302700417</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></name><name name-style="western"><surname>Gentry</surname><given-names>CA</given-names></name><name name-style="western"><surname>Plank</surname><given-names>GS</given-names></name><name name-style="western"><surname>Kraus</surname><given-names>DM</given-names></name><name name-style="western"><surname>Nickel</surname><given-names>E</given-names></name><name name-style="western"><surname>Gross</surname><given-names>JR</given-names></name></person-group><article-title>Bayesian forecasting of serum vancomycin concentrations in neonates and infants</article-title><source>Ther Drug Monit</source><year>1995</year><volume>17</volume><issue>3</issue><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1097/00007691-199506000-00005</pub-id><pub-id pub-id-type="pmid">7624919</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Rodvold KA, Gentry CA, Plank GS, Kraus DM, Nickel E, Gross JR. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit. 1995;17(3):239&#8211;46.<pub-id pub-id-type="pmid">7624919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-199506000-00005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>R</given-names></name><name name-style="western"><surname>Reis</surname><given-names>E</given-names></name><name name-style="western"><surname>Bispo</surname><given-names>M</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A</given-names></name><name name-style="western"><surname>Costa</surname><given-names>I</given-names></name><name name-style="western"><surname>Falcao</surname><given-names>F</given-names></name><etal/></person-group><article-title>The kinetic profile of vancomycin in neonates</article-title><source>J Pharm Pharmacol</source><year>1998</year><volume>50</volume><issue>11</issue><fpage>1255</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1998.tb03342.x</pub-id><pub-id pub-id-type="pmid">9877311</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Silva R, Reis E, Bispo M, Almeida A, Costa I, Falcao F, et al. The kinetic profile of vancomycin in neonates. J Pharm Pharmacol. 1998;50(11):1255&#8211;60.<pub-id pub-id-type="pmid">9877311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.2042-7158.1998.tb03342.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grimsley</surname><given-names>C</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>AH</given-names></name></person-group><article-title>Pharmacokinetics and dose requirements of vancomycin in neonates</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>1999</year><volume>81</volume><issue>3</issue><fpage>F221</fpage><lpage>F227</lpage><pub-id pub-id-type="doi">10.1136/fn.81.3.F221</pub-id><pub-id pub-id-type="pmid">10525029</pub-id><pub-id pub-id-type="pmcid">PMC1721000</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81(3):F221&#8211;7.<pub-id pub-id-type="pmid">10525029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/fn.81.3.f221</pub-id><pub-id pub-id-type="pmcid">PMC1721000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Hoog</surname><given-names>M</given-names></name><name name-style="western"><surname>Schoemaker</surname><given-names>RC</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Van Den Anker</surname><given-names>JN</given-names></name></person-group><article-title>Vancomycin population pharmacokinetics in neonates</article-title><source>Clin Pharmacol Ther</source><year>2000</year><volume>67</volume><issue>4</issue><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.105353</pub-id><pub-id pub-id-type="pmid">10801244</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">De Hoog M, Schoemaker RC, Mouton JW, Van Den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 2000;67(4):360&#8211;7.<pub-id pub-id-type="pmid">10801244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.105353</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>T</given-names></name><name name-style="western"><surname>Sunakawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>N</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>H</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>S</given-names></name><name name-style="western"><surname>Yago</surname><given-names>K</given-names></name></person-group><article-title>Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates</article-title><source>Antimicrob Agents Chemother</source><year>2004</year><volume>48</volume><issue>4</issue><fpage>1159</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.4.1159-1167.2004</pub-id><pub-id pub-id-type="pmid">15047516</pub-id><pub-id pub-id-type="pmcid">PMC375245</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004;48(4):1159&#8211;67.<pub-id pub-id-type="pmid">15047516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.48.4.1159-1167.2004</pub-id><pub-id pub-id-type="pmcid">PMC375245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Van Den Anker</surname><given-names>JN</given-names></name><name name-style="western"><surname>Vanhaesebrouck</surname><given-names>S</given-names></name><name name-style="western"><surname>De Zegher</surname><given-names>F</given-names></name></person-group><article-title>Renal drug clearance in preterm neonates: relation to prenatal growth</article-title><source>Ther Drug Monit</source><year>2007</year><volume>29</volume><issue>3</issue><fpage>284</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e31806db3f5</pub-id><pub-id pub-id-type="pmid">17529884</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Allegaert K, Anderson BJ, Van Den Anker JN, Vanhaesebrouck S, De Zegher F. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit. 2007;29(3):284&#8211;91.<pub-id pub-id-type="pmid">17529884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0b013e31806db3f5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Van Den Anker</surname><given-names>JN</given-names></name><name name-style="western"><surname>Cossey</surname><given-names>V</given-names></name><name name-style="western"><surname>Holford</surname><given-names>NHG</given-names></name></person-group><article-title>Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance</article-title><source>Br J Clin Pharmacol</source><year>2007</year><volume>63</volume><issue>1</issue><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2006.02725.x</pub-id><pub-id pub-id-type="pmid">16869817</pub-id><pub-id pub-id-type="pmcid">PMC2000709</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Anderson BJ, Allegaert K, Van Den Anker JN, Cossey V, Holford NHG. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol. 2007;63(1):75&#8211;84.<pub-id pub-id-type="pmid">16869817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2006.02725.x</pub-id><pub-id pub-id-type="pmcid">PMC2000709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marqu&#233;s-Mi&#241;ana</surname><given-names>MR</given-names></name><name name-style="western"><surname>Saadeddin</surname><given-names>A</given-names></name><name name-style="western"><surname>Peris</surname><given-names>JE</given-names></name></person-group><article-title>Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline</article-title><source>Br J Clin Pharmacol</source><year>2010</year><volume>70</volume><issue>5</issue><fpage>713</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2010.03736.x</pub-id><pub-id pub-id-type="pmid">21039765</pub-id><pub-id pub-id-type="pmcid">PMC2997311</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Marqu&#233;s-Mi&#241;ana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol. 2010;70(5):713&#8211;20.<pub-id pub-id-type="pmid">21039765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2010.03736.x</pub-id><pub-id pub-id-type="pmcid">PMC2997311</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>YL</given-names></name><name name-style="western"><surname>Van Hasselt</surname><given-names>JGC</given-names></name><name name-style="western"><surname>Heng</surname><given-names>SC</given-names></name><name name-style="western"><surname>Lim</surname><given-names>CT</given-names></name><name name-style="western"><surname>Lee</surname><given-names>TC</given-names></name><name name-style="western"><surname>Charles</surname><given-names>BG</given-names></name></person-group><article-title>Population pharmacokinetics of vancomycin in premature Malaysian neonates: Identification of predictors for dosing determination</article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><issue>6</issue><fpage>2626</fpage><lpage>2632</lpage><pub-id pub-id-type="doi">10.1128/AAC.01370-09</pub-id><pub-id pub-id-type="pmid">20385872</pub-id><pub-id pub-id-type="pmcid">PMC2876370</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Lo YL, Van Hasselt JGC, Heng SC, Lim CT, Lee TC, Charles BG. Population pharmacokinetics of vancomycin in premature Malaysian neonates: Identification of predictors for dosing determination. Antimicrob Agents Chemother. 2010;54(6):2626&#8211;32.<pub-id pub-id-type="pmid">20385872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01370-09</pub-id><pub-id pub-id-type="pmcid">PMC2876370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>E</given-names></name><name name-style="western"><surname>Biran</surname><given-names>V</given-names></name><name name-style="western"><surname>Durrmeyer</surname><given-names>X</given-names></name><name name-style="western"><surname>Fakhoury</surname><given-names>M</given-names></name><name name-style="western"><surname>Jacqz-Aigrain</surname><given-names>E</given-names></name></person-group><article-title>Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring</article-title><source>Arch Dis Child</source><year>2013</year><volume>98</volume><issue>6</issue><fpage>449</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2012-302765</pub-id><pub-id pub-id-type="pmid">23254142</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child. 2013;98(6):449&#8211;53.<pub-id pub-id-type="pmid">23254142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/archdischild-2012-302765</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frymoyer</surname><given-names>A</given-names></name><name name-style="western"><surname>Stockmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Hersh</surname><given-names>AL</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>S</given-names></name><name name-style="western"><surname>Keizer</surname><given-names>RJ</given-names></name></person-group><article-title>Individualized empiric vancomycin dosing in neonates using a model-based approach</article-title><source>J Pediatric Infect Dis Soc</source><year>2019</year><volume>8</volume><issue>2</issue><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1093/jpids/pix109</pub-id><pub-id pub-id-type="pmid">29294072</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Frymoyer A, Stockmann C, Hersh AL, Goswami S, Keizer RJ. Individualized empiric vancomycin dosing in neonates using a model-based approach. J Pediatric Infect Dis Soc. 2019;8(2):97&#8211;104.<pub-id pub-id-type="pmid">29294072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jpids/pix109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhongsatiern</surname><given-names>J</given-names></name><name name-style="western"><surname>Stockmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JK</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Korgenski</surname><given-names>KE</given-names></name><name name-style="western"><surname>Spigarelli</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration &#8805;400 target</article-title><source>Ther Drug Monit</source><year>2015</year><volume>37</volume><issue>6</issue><fpage>756</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000216</pub-id><pub-id pub-id-type="pmid">26562817</pub-id><pub-id pub-id-type="pmcid">PMC5641451</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, et al. Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration &#8805;400 target. Ther Drug Monit. 2015;37(6):756&#8211;65.<pub-id pub-id-type="pmid">26562817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0000000000000216</pub-id><pub-id pub-id-type="pmcid">PMC5641451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name><name name-style="western"><surname>Hagihara</surname><given-names>M</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>N</given-names></name><name name-style="western"><surname>Koizumi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mikamo</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates</article-title><source>J Infect Chemother</source><year>2017</year><volume>23</volume><issue>3</issue><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2016.11.009</pub-id><pub-id pub-id-type="pmid">28017667</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Kato H, Hagihara M, Nishiyama N, Koizumi Y, Mikamo H, Matsuura K, et al. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates. J Infect Chemother. 2017;23(3):154&#8211;60.<pub-id pub-id-type="pmid">28017667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jiac.2016.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Yin</surname><given-names>N-G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y-T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>62</issue><fpage>105211</fpage><lpage>105221</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.22114</pub-id><pub-id pub-id-type="pmid">29285245</pub-id><pub-id pub-id-type="pmcid">PMC5739632</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Song L, He C-Y, Yin N-G, Liu F, Jia Y-T, Liu Y. A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants. Oncotarget. 2017;8(62):105211&#8211;21.<pub-id pub-id-type="pmid">29285245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.22114</pub-id><pub-id pub-id-type="pmcid">PMC5739632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lim</surname><given-names>CP</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Kong</surname><given-names>ST</given-names></name><name name-style="western"><surname>Ho</surname><given-names>PCL</given-names></name></person-group><article-title>Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><issue>4</issue><fpage>e01647</fpage><lpage>e1717</lpage><pub-id pub-id-type="doi">10.1128/AAC.01647-17</pub-id><pub-id pub-id-type="pmid">29358290</pub-id><pub-id pub-id-type="pmcid">PMC5914004</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Tseng SH, Lim CP, Chen Q, Tang CC, Kong ST, Ho PCL. Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2018;62(4):e01647-e1717.<pub-id pub-id-type="pmid">29358290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01647-17</pub-id><pub-id pub-id-type="pmcid">PMC5914004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YX</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>G</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of vancomycin in Chinese ICU neonates: initial dosage recommendations</article-title><source>Front Pharmacol</source><year>2018</year><volume>9</volume><fpage>603</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00603</pub-id><pub-id pub-id-type="pmid">29997498</pub-id><pub-id pub-id-type="pmcid">PMC6029141</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Li ZL, Liu YX, Jiao Z, Qiu G, Huang JQ, Xiao Y, et al. Population pharmacokinetics of vancomycin in Chinese ICU neonates: initial dosage recommendations. Front Pharmacol. 2018;9:603.<pub-id pub-id-type="pmid">29997498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2018.00603</pub-id><pub-id pub-id-type="pmcid">PMC6029141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants</article-title><source>Eur J Clin Pharmacol</source><year>2018</year><volume>74</volume><issue>7</issue><fpage>921</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1007/s00228-018-2454-0</pub-id><pub-id pub-id-type="pmid">29602981</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Chen Y, Wu D, Dong M, Zhu Y, Lu J, Li X, et al. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. Eur J Clin Pharmacol. 2018;74(7):921&#8211;30.<pub-id pub-id-type="pmid">29602981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-018-2454-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reilly</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ding</surname><given-names>MX</given-names></name><name name-style="western"><surname>Rower</surname><given-names>JE</given-names></name><name name-style="western"><surname>Kiser</surname><given-names>TH</given-names></name></person-group><article-title>The Effectiveness of a vancomycin dosing guideline in the neonatal intensive care unit for achieving goal therapeutic trough concentrations</article-title><source>J Clin Pharmacol</source><year>2019</year><volume>59</volume><issue>7</issue><fpage>997</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1002/jcph.1392</pub-id><pub-id pub-id-type="pmid">30776089</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Reilly AM, Ding MX, Rower JE, Kiser TH. The Effectiveness of a vancomycin dosing guideline in the neonatal intensive care unit for achieving goal therapeutic trough concentrations. J Clin Pharmacol. 2019;59(7):997&#8211;1005.<pub-id pub-id-type="pmid">30776089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.1392</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Germovsek</surname><given-names>E</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>L</given-names></name><name name-style="western"><surname>Gunaratnam</surname><given-names>F</given-names></name><name name-style="western"><surname>Lounis</surname><given-names>SA</given-names></name><name name-style="western"><surname>Busquets</surname><given-names>FB</given-names></name><name name-style="western"><surname>Standing</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data</article-title><source>J Antimicrob Chemother</source><year>2019</year><volume>74</volume><issue>4</issue><fpage>1003</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1093/jac/dky525</pub-id><pub-id pub-id-type="pmid">30668696</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Germovsek E, Osborne L, Gunaratnam F, Lounis SA, Busquets FB, Standing JF, et al. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data. J Antimicrob Chemother. 2019;74(4):1003&#8211;11.<pub-id pub-id-type="pmid">30668696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dky525</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Back</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JB</given-names></name><name name-style="western"><surname>Han</surname><given-names>N</given-names></name><name name-style="western"><surname>Goo</surname><given-names>S</given-names></name><name name-style="western"><surname>Jung</surname><given-names>E</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>Application of size and maturation functions to population pharmacokinetic modeling of pediatric patients</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><issue>6</issue><fpage>259</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics11060259</pub-id><pub-id pub-id-type="pmid">31163633</pub-id><pub-id pub-id-type="pmcid">PMC6630378</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Back H, Lee JB, Han N, Goo S, Jung E, Kim J, et al. Application of size and maturation functions to population pharmacokinetic modeling of pediatric patients. Pharmaceutics. 2019;11(6):259.<pub-id pub-id-type="pmid">31163633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics11060259</pub-id><pub-id pub-id-type="pmcid">PMC6630378</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dao</surname><given-names>K</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>M</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>P</given-names></name><name name-style="western"><surname>Giannoni</surname><given-names>E</given-names></name><name name-style="western"><surname>Basterrechea</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Optimisation of vancomycin exposure in neonates based on the best level of evidence</article-title><source>Pharmacol Res</source><year>2020</year><volume>154</volume><fpage>104278</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104278</pub-id><pub-id pub-id-type="pmid">31108184</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Dao K, Guidi M, Andr&#233; P, Giannoni E, Basterrechea S, Zhao W, et al. Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacol Res. 2020;154: 104278.<pub-id pub-id-type="pmid">31108184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2019.104278</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulubwa</surname><given-names>M</given-names></name><name name-style="western"><surname>Griesel</surname><given-names>HA</given-names></name><name name-style="western"><surname>Mugabo</surname><given-names>P</given-names></name><name name-style="western"><surname>Dippenaar</surname><given-names>R</given-names></name><name name-style="western"><surname>van Wyk</surname><given-names>L</given-names></name></person-group><article-title>Assessment of vancomycin pharmacokinetics and dose regimen optimisation in preterm neonates</article-title><source>Drugs R D.</source><year>2020</year><volume>20</volume><issue>2</issue><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1007/s40268-020-00302-7</pub-id><pub-id pub-id-type="pmid">32266599</pub-id><pub-id pub-id-type="pmcid">PMC7221111</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Mulubwa M, Griesel HA, Mugabo P, Dippenaar R, van Wyk L. Assessment of vancomycin pharmacokinetics and dose regimen optimisation in preterm neonates. Drugs R D. 2020;20(2):105&#8211;13.<pub-id pub-id-type="pmid">32266599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40268-020-00302-7</pub-id><pub-id pub-id-type="pmcid">PMC7221111</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasano</surname><given-names>H</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>K</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>R</given-names></name><name name-style="western"><surname>Hanada</surname><given-names>K</given-names></name></person-group><article-title>Population pharmacokinetic analysis and dose regimen optimization in japanese infants with an extremely low birth weight</article-title><source>Antimicrob Agents Chemother</source><year>2021</year><volume>65</volume><issue>3</issue><fpage>e02523</fpage><lpage>e2620</lpage><pub-id pub-id-type="doi">10.1128/AAC.02523-20</pub-id><pub-id pub-id-type="pmid">33318009</pub-id><pub-id pub-id-type="pmcid">PMC8092535</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Sasano H, Aoki K, Arakawa R, Hanada K. Population pharmacokinetic analysis and dose regimen optimization in japanese infants with an extremely low birth weight. Antimicrob Agents Chemother. 2021;65(3):e02523-e2620.<pub-id pub-id-type="pmid">33318009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02523-20</pub-id><pub-id pub-id-type="pmcid">PMC8092535</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsultan</surname><given-names>A</given-names></name><name name-style="western"><surname>Al Munjem</surname><given-names>MF</given-names></name><name name-style="western"><surname>Atiq</surname><given-names>KM</given-names></name><name name-style="western"><surname>Aljehani</surname><given-names>ZK</given-names></name><name name-style="western"><surname>Al Muqati</surname><given-names>H</given-names></name><name name-style="western"><surname>Almohaizeie</surname><given-names>A</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of vancomycin in very low birth weight neonates</article-title><source>Front Pediatr</source><year>2023</year><volume>30</volume><issue>11</issue><fpage>1093171</fpage><pub-id pub-id-type="doi">10.3389/fped.2023.1093171</pub-id><pub-id pub-id-type="pmcid">PMC10101232</pub-id><pub-id pub-id-type="pmid">37063687</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Alsultan A, Al Munjem MF, Atiq KM, Aljehani ZK, Al Muqati H, Almohaizeie A, et al. Population pharmacokinetics of vancomycin in very low birth weight neonates. Front Pediatr. 2023;30(11):1093171.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2023.1093171</pub-id><pub-id pub-id-type="pmcid">PMC10101232</pub-id><pub-id pub-id-type="pmid">37063687</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>E</given-names></name><name name-style="western"><surname>Seto</surname><given-names>W</given-names></name></person-group><article-title>Using population pharmacokinetics to optimize initial vancomycin dosing guidelines for neonates to treat sepsis caused by coagulase-negative staphylococcus</article-title><source>Pharmacotherapy</source><year>2023</year><volume>43</volume><issue>12</issue><fpage>1262</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1002/phar.2865</pub-id><pub-id pub-id-type="pmid">37574774</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Chung E, Seto W. Using population pharmacokinetics to optimize initial vancomycin dosing guidelines for neonates to treat sepsis caused by coagulase-negative staphylococcus. Pharmacotherapy. 2023;43(12):1262&#8211;76.<pub-id pub-id-type="pmid">37574774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.2865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodge</surname><given-names>WF</given-names></name><name name-style="western"><surname>Jelliffe</surname><given-names>RW</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>McCleery</surname><given-names>RA</given-names></name><name name-style="western"><surname>Hokanson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Snodgrass</surname><given-names>WR</given-names></name></person-group><article-title>Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method</article-title><source>Clin Pharmacol Ther</source><year>1991</year><volume>50</volume><issue>1</issue><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/clpt.1991.100</pub-id><pub-id pub-id-type="pmid">1855350</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Dodge WF, Jelliffe RW, Richardson CJ, McCleery RA, Hokanson JA, Snodgrass WR. Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clin Pharmacol Ther. 1991;50(1):25&#8211;31.<pub-id pub-id-type="pmid">1855350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1991.100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>PD</given-names></name><name name-style="western"><surname>Edgren</surname><given-names>BE</given-names></name><name name-style="western"><surname>Brundage</surname><given-names>RC</given-names></name></person-group><article-title>Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model</article-title><source>Pharmacotherapy</source><year>1992</year><volume>12</volume><issue>3</issue><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1002/j.1875-9114.1992.tb04506.x</pub-id><pub-id pub-id-type="pmid">1608849</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Jensen PD, Edgren BE, Brundage RC. Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model. Pharmacotherapy. 1992;12(3):178&#8211;82.<pub-id pub-id-type="pmid">1608849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></name><name name-style="western"><surname>Gentrya</surname><given-names>C</given-names></name><name name-style="western"><surname>Plank</surname><given-names>G</given-names></name><name name-style="western"><surname>Kraus</surname><given-names>D</given-names></name><name name-style="western"><surname>Nickel</surname><given-names>E</given-names></name><name name-style="western"><surname>Gross</surname><given-names>J</given-names></name></person-group><article-title>Prediction of gentamicin concentrations in neonates and infants using a bayesian pharmacokinetic model</article-title><source>Dev Pharmacol Ther</source><year>1993</year><volume>20</volume><issue>3&#8211;4</issue><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1159/000457565</pub-id><pub-id pub-id-type="pmid">7828456</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Rodvold KA, Gentrya C, Plank G, Kraus D, Nickel E, Gross J. Prediction of gentamicin concentrations in neonates and infants using a bayesian pharmacokinetic model. Dev Pharmacol Ther. 1993;20(3&#8211;4):211&#8211;9.<pub-id pub-id-type="pmid">7828456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000457565</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>W</given-names></name><name name-style="western"><surname>Kewitz</surname><given-names>G</given-names></name><name name-style="western"><surname>Rost</surname><given-names>KL</given-names></name><name name-style="western"><surname>Looby</surname><given-names>M</given-names></name><name name-style="western"><surname>Nitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Harnisch</surname><given-names>L</given-names></name></person-group><article-title>Population kinetics of gentamicin in neonates</article-title><source>Eur J Clin Pharmacol</source><year>1993</year><volume>44</volume><issue>Suppl 1</issue><fpage>S23</fpage><lpage>S25</lpage><pub-id pub-id-type="doi">10.1007/BF01428387</pub-id><pub-id pub-id-type="pmid">8486141</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Weber W, Kewitz G, Rost KL, Looby M, Nitz M, Harnisch L. Population kinetics of gentamicin in neonates. Eur J Clin Pharmacol. 1993;44(Suppl 1):S23&#8211;5.<pub-id pub-id-type="pmid">8486141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01428387</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vervelde</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rademaker</surname><given-names>CMA</given-names></name><name name-style="western"><surname>Krediet</surname><given-names>TG</given-names></name><name name-style="western"><surname>Fleer</surname><given-names>A</given-names></name><name name-style="western"><surname>van Asten</surname><given-names>P</given-names></name><name name-style="western"><surname>van Dijk</surname><given-names>A</given-names></name></person-group><article-title>Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen</article-title><source>Ther Drug Monit</source><year>1999</year><volume>21</volume><issue>5</issue><fpage>514</fpage><pub-id pub-id-type="doi">10.1097/00007691-199910000-00004</pub-id><pub-id pub-id-type="pmid">10519447</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Vervelde ML, Rademaker CMA, Krediet TG, Fleer A, van Asten P, van Dijk A. Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen. Ther Drug Monit. 1999;21(5):514.<pub-id pub-id-type="pmid">10519447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-199910000-00004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stickland</surname><given-names>MD</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>C</given-names></name><name name-style="western"><surname>Begg</surname><given-names>E</given-names></name><name name-style="western"><surname>Duffull</surname><given-names>S</given-names></name><name name-style="western"><surname>Oddie</surname><given-names>S</given-names></name><name name-style="western"><surname>Darlow</surname><given-names>B</given-names></name></person-group><article-title>An extended interval dosing method for gentamicin in neonates</article-title><source>J Antimicrob Chemother</source><year>2001</year><volume>48</volume><issue>6</issue><fpage>887</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1093/jac/48.6.887</pub-id><pub-id pub-id-type="pmid">11733474</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Stickland MD, Kirkpatrick C, Begg E, Duffull S, Oddie S, Darlow B. An extended interval dosing method for gentamicin in neonates. J Antimicrob Chemother. 2001;48(6):887&#8211;93.<pub-id pub-id-type="pmid">11733474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/48.6.887</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stolk</surname><given-names>L</given-names></name><name name-style="western"><surname>Degraeuwe</surname><given-names>P</given-names></name><name name-style="western"><surname>Nieman</surname><given-names>F</given-names></name><name name-style="western"><surname>De Wolf</surname><given-names>M</given-names></name><name name-style="western"><surname>De Boer</surname><given-names>A</given-names></name></person-group><article-title>Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates</article-title><source>Ther Drug Monit</source><year>2002</year><volume>24</volume><issue>4</issue><fpage>527</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1097/00007691-200208000-00011</pub-id><pub-id pub-id-type="pmid">12142638</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Stolk L, Degraeuwe P, Nieman F, De Wolf M, De Boer A. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit. 2002;24(4):527&#8211;31.<pub-id pub-id-type="pmid">12142638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-200208000-00011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botha</surname><given-names>JH</given-names></name><name name-style="western"><surname>Du Preez</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>M</given-names></name></person-group><article-title>Population pharmacokinetics of gentamicin in South African newborns</article-title><source>Eur J Clin Pharmacol</source><year>2003</year><volume>59</volume><issue>10</issue><fpage>755</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1007/s00228-003-0663-6</pub-id><pub-id pub-id-type="pmid">14566440</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Botha JH, Du Preez MJ, Adhikari M. Population pharmacokinetics of gentamicin in South African newborns. Eur J Clin Pharmacol. 2003;59(10):755&#8211;9.<pub-id pub-id-type="pmid">14566440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-003-0663-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiCenzo</surname><given-names>R</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Slish</surname><given-names>JC</given-names></name><name name-style="western"><surname>Cole</surname><given-names>C</given-names></name><name name-style="western"><surname>Guillet</surname><given-names>R</given-names></name></person-group><article-title>A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates</article-title><source>Pharmacotherapy</source><year>2003</year><volume>23</volume><issue>5</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1592/phco.23.5.585.32196</pub-id><pub-id pub-id-type="pmid">12741432</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">DiCenzo R, Forrest A, Slish JC, Cole C, Guillet R. A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. Pharmacotherapy. 2003;23(5):585&#8211;91.<pub-id pub-id-type="pmid">12741432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1592/phco.23.5.585.32196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lanao</surname><given-names>JM</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>MV</given-names></name><name name-style="western"><surname>Mesa</surname><given-names>JA</given-names></name><name name-style="western"><surname>Mart&#237;n-Su&#225;rez</surname><given-names>A</given-names></name><name name-style="western"><surname>Carbajosa</surname><given-names>MT</given-names></name><name name-style="western"><surname>Miguelez</surname><given-names>F</given-names></name><etal/></person-group><article-title>Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates</article-title><source>J Antimicrob Chemother</source><year>2004</year><volume>54</volume><issue>1</issue><fpage>193</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh261</pub-id><pub-id pub-id-type="pmid">15150171</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Lanao JM, Calvo MV, Mesa JA, Mart&#237;n-Su&#225;rez A, Carbajosa MT, Miguelez F, et al. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. J Antimicrob Chemother. 2004;54(1):193&#8211;8.<pub-id pub-id-type="pmid">15150171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkh261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lingvall</surname><given-names>M</given-names></name><name name-style="western"><surname>Reith</surname><given-names>D</given-names></name><name name-style="western"><surname>Broadbent</surname><given-names>R</given-names></name></person-group><article-title>The effect of sepsis upon gentamicin pharmacokinetics in neonates</article-title><source>Br J Clin Pharmacol</source><year>2005</year><volume>59</volume><issue>1</issue><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2005.02260.x</pub-id><pub-id pub-id-type="pmid">15606440</pub-id><pub-id pub-id-type="pmcid">PMC1884965</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol. 2005;59(1):54&#8211;61.<pub-id pub-id-type="pmid">15606440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2005.02260.x</pub-id><pub-id pub-id-type="pmcid">PMC1884965</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a</surname><given-names>B</given-names></name><name name-style="western"><surname>Barcia</surname><given-names>E</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>F</given-names></name><name name-style="western"><surname>Molina</surname><given-names>IT</given-names></name></person-group><article-title>Population pharmacokinetics of gentamicin in premature newborns</article-title><source>J Antimicrob Chemother</source><year>2006</year><volume>58</volume><issue>2</issue><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl244</pub-id><pub-id pub-id-type="pmid">16782742</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Garc&#237;a B, Barcia E, P&#233;rez F, Molina IT. Population pharmacokinetics of gentamicin in premature newborns. J Antimicrob Chemother. 2006;58(2):372&#8211;9.<pub-id pub-id-type="pmid">16782742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkl244</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>EI</given-names></name><name name-style="western"><surname>Sandstr&#246;m</surname><given-names>M</given-names></name><name name-style="western"><surname>Honor&#233;</surname><given-names>H</given-names></name><name name-style="western"><surname>Ewald</surname><given-names>U</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name></person-group><article-title>Developmental pharmacokinetics of gentamicin in preterm and term neonates population modelling of a prospective study</article-title><source>Clin Pharmacokinet</source><year>2009</year><volume>48</volume><issue>4</issue><fpage>253</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.2165/00003088-200948040-00003</pub-id><pub-id pub-id-type="pmid">19492870</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Nielsen EI, Sandstr&#246;m M, Honor&#233; H, Ewald U, Friberg LE. Developmental pharmacokinetics of gentamicin in preterm and term neonates population modelling of a prospective study. Clin Pharmacokinet. 2009;48(4):253&#8211;63.<pub-id pub-id-type="pmid">19492870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200948040-00003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherwin</surname><given-names>CMT</given-names></name><name name-style="western"><surname>Kostan</surname><given-names>E</given-names></name><name name-style="western"><surname>Broadbent</surname><given-names>RS</given-names></name><name name-style="western"><surname>Medlicott</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Reith</surname><given-names>DM</given-names></name></person-group><article-title>Evaluation of the effect of intravenous volume expanders upon the volume of distribution of gentamicin in septic neonates</article-title><source>Biopharm Drug Dispos</source><year>2009</year><volume>30</volume><issue>5</issue><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1002/bdd.666</pub-id><pub-id pub-id-type="pmid">19544484</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Sherwin CMT, Kostan E, Broadbent RS, Medlicott NJ, Reith DM. Evaluation of the effect of intravenous volume expanders upon the volume of distribution of gentamicin in septic neonates. Biopharm Drug Dispos. 2009;30(5):276&#8211;80.<pub-id pub-id-type="pmid">19544484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bdd.666</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Germovsek</surname><given-names>E</given-names></name><name name-style="western"><surname>Kent</surname><given-names>A</given-names></name><name name-style="western"><surname>Metsvaht</surname><given-names>T</given-names></name><name name-style="western"><surname>Lutsar</surname><given-names>I</given-names></name><name name-style="western"><surname>Klein</surname><given-names>N</given-names></name><name name-style="western"><surname>Turner</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><issue>8</issue><fpage>4869</fpage><lpage>4877</lpage><pub-id pub-id-type="doi">10.1128/AAC.00577-16</pub-id><pub-id pub-id-type="pmid">27270281</pub-id><pub-id pub-id-type="pmcid">PMC4958175</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Germovsek E, Kent A, Metsvaht T, Lutsar I, Klein N, Turner MA, et al. Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants. Antimicrob Agents Chemother. 2016;60(8):4869&#8211;77.<pub-id pub-id-type="pmid">27270281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00577-16</pub-id><pub-id pub-id-type="pmcid">PMC4958175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bijleveld</surname><given-names>YA</given-names></name><name name-style="western"><surname>Van Den Heuvel</surname><given-names>ME</given-names></name><name name-style="western"><surname>Hodiamont</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Math&#244;t</surname><given-names>RAA</given-names></name><name name-style="western"><surname>De Haan</surname><given-names>TR</given-names></name></person-group><article-title>Population pharmacokinetics and dosing considerations for gentamicin in newborns with suspected or proven sepsis caused by gram-negative bacteria</article-title><source>Antimicrob Agents Chemother</source><year>2017</year><volume>61</volume><issue>1</issue><fpage>e01304</fpage><lpage>e1316</lpage><pub-id pub-id-type="doi">10.1128/AAC.01304-16</pub-id><pub-id pub-id-type="pmid">27795373</pub-id><pub-id pub-id-type="pmcid">PMC5192127</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Bijleveld YA, Van Den Heuvel ME, Hodiamont CJ, Math&#244;t RAA, De Haan TR. Population pharmacokinetics and dosing considerations for gentamicin in newborns with suspected or proven sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother. 2017;61(1):e01304-e1316.<pub-id pub-id-type="pmid">27795373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01304-16</pub-id><pub-id pub-id-type="pmcid">PMC5192127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assael</surname><given-names>B</given-names></name><name name-style="western"><surname>Parini</surname><given-names>R</given-names></name><name name-style="western"><surname>Rusconi</surname><given-names>F</given-names></name><name name-style="western"><surname>Cavanna</surname><given-names>G</given-names></name></person-group><article-title>Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period</article-title><source>Pediatr Res</source><year>1982</year><volume>16</volume><fpage>810</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1203/00006450-198210000-00002</pub-id><pub-id pub-id-type="pmid">7145504</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Assael B, Parini R, Rusconi F, Cavanna G. Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period. Pediatr Res. 1982;16:810&#8211;5.<pub-id pub-id-type="pmid">7145504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1203/00006450-198210000-00002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenyon</surname><given-names>CF</given-names></name><name name-style="western"><surname>Knoppert</surname><given-names>DC</given-names></name><name name-style="western"><surname>Kim Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>HM</given-names></name><name name-style="western"><surname>Chance</surname><given-names>GW</given-names></name></person-group><article-title>Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant</article-title><source>Antimicrob Agents Chemother</source><year>1990</year><volume>34</volume><issue>2</issue><fpage>265</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1128/AAC.34.2.265</pub-id><pub-id pub-id-type="pmid">2327775</pub-id><pub-id pub-id-type="pmcid">PMC171570</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Kenyon CF, Knoppert DC, Kim Lee S, Vandenberghe HM, Chance GW. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother. 1990;34(2):265&#8211;8.<pub-id pub-id-type="pmid">2327775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.34.2.265</pub-id><pub-id pub-id-type="pmcid">PMC171570</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botha</surname><given-names>JH</given-names></name><name name-style="western"><surname>Du Preez</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>M</given-names></name></person-group><article-title>Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models</article-title><source>Eur J Clin Pharmacol</source><year>1998</year><volume>53</volume><issue>5</issue><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1007/s002280050389</pub-id><pub-id pub-id-type="pmid">9516033</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Botha JH, Du Preez MJ, Miller R, Adhikari M. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. Eur J Clin Pharmacol. 1998;53(5):337&#8211;41.<pub-id pub-id-type="pmid">9516033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280050389</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Cossey</surname><given-names>V</given-names></name><name name-style="western"><surname>Holford</surname><given-names>NHG</given-names></name></person-group><article-title>Limited predictability of amikacin clearance in extreme premature neonates at birth</article-title><source>Br J Clin Pharmacol</source><year>2006</year><volume>61</volume><issue>1</issue><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2005.02530.x</pub-id><pub-id pub-id-type="pmid">16390350</pub-id><pub-id pub-id-type="pmcid">PMC1884978</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Allegaert K, Anderson BJ, Cossey V, Holford NHG. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol. 2006;61(1):39&#8211;48.<pub-id pub-id-type="pmid">16390350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2005.02530.x</pub-id><pub-id pub-id-type="pmcid">PMC1884978</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Scheers</surname><given-names>I</given-names></name><name name-style="western"><surname>Cossey</surname><given-names>V</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name></person-group><article-title>Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability</article-title><source>Drug Metab Lett</source><year>2008</year><volume>2</volume><issue>4</issue><fpage>286</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.2174/187231208786734157</pub-id><pub-id pub-id-type="pmid">19356107</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Allegaert K, Scheers I, Cossey V, Anderson BJ. Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability. Drug Metab Lett. 2008;2(4):286&#8211;9.<pub-id pub-id-type="pmid">19356107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/187231208786734157</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherwin</surname><given-names>CMT</given-names></name><name name-style="western"><surname>Svahn</surname><given-names>S</given-names></name><name name-style="western"><surname>Van Der Linden</surname><given-names>A</given-names></name><name name-style="western"><surname>Broadbent</surname><given-names>RS</given-names></name><name name-style="western"><surname>Medlicott</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Reith</surname><given-names>DM</given-names></name></person-group><article-title>Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis</article-title><source>Eur J Clin Pharmacol</source><year>2009</year><volume>65</volume><issue>7</issue><fpage>705</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1007/s00228-009-0637-4</pub-id><pub-id pub-id-type="pmid">19305985</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Sherwin CMT, Svahn S, Van Der Linden A, Broadbent RS, Medlicott NJ, Reith DM. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol. 2009;65(7):705&#8211;13.<pub-id pub-id-type="pmid">19305985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-009-0637-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amponsah</surname><given-names>SK</given-names></name><name name-style="western"><surname>Adjei</surname><given-names>GO</given-names></name><name name-style="western"><surname>Enweronu-Laryea</surname><given-names>C</given-names></name><name name-style="western"><surname>Bugyei</surname><given-names>KA</given-names></name><name name-style="western"><surname>Hadji-Popovski</surname><given-names>K</given-names></name><name name-style="western"><surname>Kurtzhals</surname><given-names>JAL</given-names></name><etal/></person-group><article-title>Population pharmacokinetic characteristics of amikacin in suspected cases of neonatal sepsis in a low-resource African setting: a prospective nonrandomized single-site study</article-title><source>Curr Ther Res Clin Exp</source><year>2017</year><volume>84</volume><fpage>e1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.curtheres.2017.01.001</pub-id><pub-id pub-id-type="pmid">28761582</pub-id><pub-id pub-id-type="pmcid">PMC5522970</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Amponsah SK, Adjei GO, Enweronu-Laryea C, Bugyei KA, Hadji-Popovski K, Kurtzhals JAL, et al. Population pharmacokinetic characteristics of amikacin in suspected cases of neonatal sepsis in a low-resource African setting: a prospective nonrandomized single-site study. Curr Ther Res Clin Exp. 2017;84:e1-6.<pub-id pub-id-type="pmid">28761582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.curtheres.2017.01.001</pub-id><pub-id pub-id-type="pmcid">PMC5522970</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caceres-Guido</surname><given-names>P</given-names></name><name name-style="western"><surname>Travaglianti</surname><given-names>M</given-names></name><name name-style="western"><surname>Castro</surname><given-names>G</given-names></name><name name-style="western"><surname>Licciardone</surname><given-names>N</given-names></name><name name-style="western"><surname>Ferreyra</surname><given-names>O</given-names></name><name name-style="western"><surname>Vietri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Population pharmacokinetic study of vancomycin in preterm neonates</article-title><source>Am J Pharm</source><year>2015</year><volume>34</volume><issue>1</issue><fpage>124</fpage><lpage>157</lpage></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Caceres-Guido P, Travaglianti M, Castro G, Licciardone N, Ferreyra O, Vietri S, et al. Population pharmacokinetic study of vancomycin in preterm neonates. Am J Pharm. 2015;34(1):124&#8211;57.</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Severino</surname><given-names>N</given-names></name><name name-style="western"><surname>Urz&#250;a</surname><given-names>S</given-names></name><name name-style="western"><surname>Ibacache</surname><given-names>M</given-names></name><name name-style="western"><surname>Paulos</surname><given-names>C</given-names></name><name name-style="western"><surname>Cort&#237;nez</surname><given-names>L</given-names></name><name name-style="western"><surname>Toso</surname><given-names>A</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of amikacin in suspected cases of neonatal sepsis</article-title><source>Br J Clin Pharmacol</source><year>2023</year><volume>89</volume><issue>7</issue><fpage>2254</fpage><lpage>2262</lpage><pub-id pub-id-type="doi">10.1111/bcp.15697</pub-id><pub-id pub-id-type="pmid">36811146</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Severino N, Urz&#250;a S, Ibacache M, Paulos C, Cort&#237;nez L, Toso A, et al. Population pharmacokinetics of amikacin in suspected cases of neonatal sepsis. Br J Clin Pharmacol. 2023;89(7):2254&#8211;62.<pub-id pub-id-type="pmid">36811146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.15697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehrotra</surname><given-names>N</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Meibohm</surname><given-names>B</given-names></name></person-group><article-title>Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations</article-title><source>Pharmacotherapy</source><year>2012</year><volume>32</volume><issue>5</issue><fpage>408</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1002/j.1875-9114.2012.01029.x</pub-id><pub-id pub-id-type="pmid">22488303</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Mehrotra N, Tang L, Phelps SJ, Meibohm B. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy. 2012;32(5):408&#8211;19.<pub-id pub-id-type="pmid">22488303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1875-9114.2012.01029.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frymoyer</surname><given-names>A</given-names></name><name name-style="western"><surname>Hersh</surname><given-names>AL</given-names></name><name name-style="western"><surname>El-Komy</surname><given-names>MH</given-names></name><name name-style="western"><surname>Gaskari</surname><given-names>S</given-names></name><name name-style="western"><surname>Su</surname><given-names>F</given-names></name><name name-style="western"><surname>Drover</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Association between vancomycin trough concentration and area under the concentration-time curve in neonates</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>11</issue><fpage>6454</fpage><lpage>6461</lpage><pub-id pub-id-type="doi">10.1128/AAC.03620-14</pub-id><pub-id pub-id-type="pmid">25136027</pub-id><pub-id pub-id-type="pmcid">PMC4249374</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, et al. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2014;58(11):6454&#8211;61.<pub-id pub-id-type="pmid">25136027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.03620-14</pub-id><pub-id pub-id-type="pmcid">PMC4249374</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Holford</surname><given-names>NHG</given-names></name></person-group><article-title>Mechanism-based concepts of size and maturity in pharmacokinetics</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2008</year><volume>48</volume><issue>1</issue><fpage>303</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.48.113006.094708</pub-id><pub-id pub-id-type="pmid">17914927</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48(1):303&#8211;32.<pub-id pub-id-type="pmid">17914927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.pharmtox.48.113006.094708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moffett</surname><given-names>BS</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>F</given-names></name><name name-style="western"><surname>Arikan</surname><given-names>AA</given-names></name></person-group><article-title>Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy</article-title><source>Eur J Clin Pharmacol</source><year>2019</year><volume>75</volume><issue>8</issue><fpage>1089</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1007/s00228-019-02664-7</pub-id><pub-id pub-id-type="pmid">30937470</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Moffett BS, Morris J, Munoz F, Arikan AA. Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy. Eur J Clin Pharmacol. 2019;75(8):1089&#8211;97.<pub-id pub-id-type="pmid">30937470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-019-02664-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moffett</surname><given-names>BS</given-names></name><name name-style="western"><surname>Resendiz</surname><given-names>K</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J</given-names></name><name name-style="western"><surname>Akcan-Arikan</surname><given-names>A</given-names></name><name name-style="western"><surname>Checchia</surname><given-names>PA</given-names></name></person-group><article-title>Population pharmacokinetics of vancomycin in the pediatric cardiac surgical population</article-title><source>J Pediatr Pharmacol Ther</source><year>2019</year><volume>24</volume><issue>2</issue><fpage>107</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">31019403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5863/1551-6776-24.2.107</pub-id><pub-id pub-id-type="pmcid">PMC6478363</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Moffett BS, Resendiz K, Morris J, Akcan-Arikan A, Checchia PA. Population pharmacokinetics of vancomycin in the pediatric cardiac surgical population. J Pediatr Pharmacol Ther. 2019;24(2):107&#8211;16.<pub-id pub-id-type="pmid">31019403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5863/1551-6776-24.2.107</pub-id><pub-id pub-id-type="pmcid">PMC6478363</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhodin</surname><given-names>MM</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Peters</surname><given-names>AM</given-names></name><name name-style="western"><surname>Coulthard</surname><given-names>MG</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>B</given-names></name><name name-style="western"><surname>Cole</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human renal function maturation: a quantitative description using weight and postmenstrual age</article-title><source>Pediatr Nephrol</source><year>2009</year><volume>24</volume><issue>1</issue><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s00467-008-0997-5</pub-id><pub-id pub-id-type="pmid">18846389</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67&#8211;76.<pub-id pub-id-type="pmid">18846389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00467-008-0997-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>SS</given-names></name><name name-style="western"><surname>Sherwin</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ward</surname><given-names>R</given-names></name><name name-style="western"><surname>Baer</surname><given-names>G</given-names></name><name name-style="western"><surname>Burckart</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Renal clearance in newborns and infants: predictive performance of population-based modeling for drug development</article-title><source>Clin Pharmacol Ther</source><year>2019</year><volume>105</volume><issue>6</issue><fpage>1462</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1002/cpt.1332</pub-id><pub-id pub-id-type="pmid">30565653</pub-id><pub-id pub-id-type="pmcid">PMC6513721</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Wang J, Kumar SS, Sherwin CM, Ward R, Baer G, Burckart GJ, et al. Renal clearance in newborns and infants: predictive performance of population-based modeling for drug development. Clin Pharmacol Ther. 2019;105(6):1462&#8211;70.<pub-id pub-id-type="pmid">30565653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1332</pub-id><pub-id pub-id-type="pmcid">PMC6513721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hanlon</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Holford</surname><given-names>N</given-names></name><name name-style="western"><surname>Sumpter</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Sallami</surname><given-names>HS</given-names></name></person-group><article-title>Consistent methods for fat-free mass, creatinine clearance, and glomerular filtration rate to describe renal function from neonates to adults</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2023</year><volume>12</volume><issue>3</issue><fpage>401</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1002/psp4.12924</pub-id><pub-id pub-id-type="pmid">36691877</pub-id><pub-id pub-id-type="pmcid">PMC10014044</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">O&#8217;Hanlon CJ, Holford N, Sumpter A, Al-Sallami HS. Consistent methods for fat-free mass, creatinine clearance, and glomerular filtration rate to describe renal function from neonates to adults. CPT Pharmacometrics Syst Pharmacol. 2023;12(3):401&#8211;12.<pub-id pub-id-type="pmid">36691877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12924</pub-id><pub-id pub-id-type="pmcid">PMC10014044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guignard</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Drukker</surname><given-names>A</given-names></name></person-group><article-title>Why do newborn infants have a high plasma creatinine?</article-title><source>Pediatrics</source><year>1999</year><volume>103</volume><issue>4</issue><fpage>e49</fpage><lpage>e49</lpage><pub-id pub-id-type="doi">10.1542/peds.103.4.e49</pub-id><pub-id pub-id-type="pmid">10103341</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Guignard J-P, Drukker A. Why do newborn infants have a high plasma creatinine? Pediatrics. 1999;103(4):e49&#8211;e49.<pub-id pub-id-type="pmid">10103341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.103.4.e49</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batchelor</surname><given-names>HK</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>JF</given-names></name></person-group><article-title>Paediatric pharmacokinetics: key considerations</article-title><source>Br J Clin Pharmacol</source><year>2015</year><volume>79</volume><issue>3</issue><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1111/bcp.12267</pub-id><pub-id pub-id-type="pmid">25855821</pub-id><pub-id pub-id-type="pmcid">PMC4345950</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395&#8211;404.<pub-id pub-id-type="pmid">25855821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.12267</pub-id><pub-id pub-id-type="pmcid">PMC4345950</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><mixed-citation publication-type="other">Murphy John E. Clinical Pharmacokinetics. 6 ed. Bethesda, MD: American Society of Health-System Pharmacists (ASHP); 2017.</mixed-citation></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Morselli</surname><given-names>P</given-names></name><name name-style="western"><surname>Morselli</surname><given-names>R</given-names></name><name name-style="western"><surname>Bossi</surname><given-names>L</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Gibaldi</surname><given-names>M</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>L</given-names></name></person-group><article-title>Clinical pharmacokinetics in newborns and infants</article-title><source>Handbook of clinical pharmacokinetics, section II</source><year>1983</year><publisher-loc>New York</publisher-loc><publisher-name>ADIS Health Sciences Press</publisher-name></element-citation><mixed-citation id="mc-CR96" publication-type="book">Morselli P, Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. In: Gibaldi M, Prescott L, editors. Handbook of clinical pharmacokinetics, section II. New York: ADIS Health Sciences Press; 1983.</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghoneim</surname><given-names>RH</given-names></name><name name-style="western"><surname>Thabit</surname><given-names>AK</given-names></name><name name-style="western"><surname>Lashkar</surname><given-names>MO</given-names></name><name name-style="western"><surname>Ali</surname><given-names>AS</given-names></name></person-group><article-title>Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation</article-title><source>Ital J Pediatr</source><year>2021</year><volume>47</volume><issue>1</issue><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/s13052-021-01114-4</pub-id><pub-id pub-id-type="pmid">34362436</pub-id><pub-id pub-id-type="pmcid">PMC8343923</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Ghoneim RH, Thabit AK, Lashkar MO, Ali AS. Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation. Ital J Pediatr. 2021;47(1):167.<pub-id pub-id-type="pmid">34362436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13052-021-01114-4</pub-id><pub-id pub-id-type="pmcid">PMC8343923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacifici</surname><given-names>GM</given-names></name></person-group><article-title>Clinical pharmacokinetics of aminoglycosides in the neonate: a review</article-title><source>Eur J Clin Pharmacol</source><year>2009</year><volume>65</volume><issue>4</issue><fpage>419</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1007/s00228-008-0599-y</pub-id><pub-id pub-id-type="pmid">19104791</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Pacifici GM. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol. 2009;65(4):419&#8211;27.<pub-id pub-id-type="pmid">19104791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-008-0599-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iacobelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Guignard</surname><given-names>J-P</given-names></name></person-group><article-title>Maturation of glomerular filtration rate in neonates and infants: an overview</article-title><source>Pediatr Nephrol</source><year>2021</year><volume>36</volume><issue>6</issue><fpage>1439</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1007/s00467-020-04632-1</pub-id><pub-id pub-id-type="pmid">32529323</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Iacobelli S, Guignard J-P. Maturation of glomerular filtration rate in neonates and infants: an overview. Pediatr Nephrol. 2021;36(6):1439&#8211;46.<pub-id pub-id-type="pmid">32529323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00467-020-04632-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDougal</surname><given-names>A</given-names></name><name name-style="western"><surname>Ling</surname><given-names>EW</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M</given-names></name></person-group><article-title>Vancomycin pharmacokinetics and dosing in premature neonates</article-title><source>Ther Drug Monit</source><year>1995</year><volume>17</volume><issue>4</issue><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1097/00007691-199508000-00001</pub-id><pub-id pub-id-type="pmid">7482683</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit. 1995;17(4):319&#8211;26.<pub-id pub-id-type="pmid">7482683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-199508000-00001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayak-Rao</surname><given-names>S</given-names></name></person-group><article-title>Aminoglycoside use in renal failure</article-title><source>Indian J Nephrol.</source><year>2010</year><volume>20</volume><issue>3</issue><fpage>121</fpage><pub-id pub-id-type="doi">10.4103/0971-4065.70839</pub-id><pub-id pub-id-type="pmid">21072150</pub-id><pub-id pub-id-type="pmcid">PMC2966976</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Nayak-Rao S. Aminoglycoside use in renal failure. Indian J Nephrol. 2010;20(3):121.<pub-id pub-id-type="pmid">21072150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0971-4065.70839</pub-id><pub-id pub-id-type="pmcid">PMC2966976</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Hoog</surname><given-names>M</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Van Den Anker</surname><given-names>JN</given-names></name></person-group><article-title>Vancomycin pharmacokinetics and administration regimens in neonates</article-title><source>Clin Pharmacokinet</source><year>2004</year><volume>43</volume><issue>7</issue><fpage>417</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">15139793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200443070-00001</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">De Hoog M, Mouton JW, Van Den Anker JN. Vancomycin pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43(7):417&#8211;40.<pub-id pub-id-type="pmid">15139793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200443070-00001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacqz-Aigrain</surname><given-names>E</given-names></name><name name-style="western"><surname>Leroux</surname><given-names>S</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>AH</given-names></name><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name><name name-style="western"><surname>Capparelli</surname><given-names>EV</given-names></name><name name-style="western"><surname>Biran</surname><given-names>V</given-names></name><etal/></person-group><article-title>Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants</article-title><source>J Antimicrob Chemother</source><year>2019</year><volume>74</volume><issue>8</issue><fpage>2128</fpage><lpage>2138</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz158</pub-id><pub-id pub-id-type="pmid">31049551</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Jacqz-Aigrain E, Leroux S, Thomson AH, Allegaert K, Capparelli EV, Biran V, et al. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. J Antimicrob Chemother. 2019;74(8):2128&#8211;38.<pub-id pub-id-type="pmid">31049551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkz158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><mixed-citation publication-type="other">US FDA. Guidance for industry: population pharmacokinetics. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/Guidances/UCM072137.pdf">http://www.fda.gov/downloads/Drugs/Guidances/UCM072137.pdf</ext-link>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>